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Resumo 
A doença de Huntington é uma doença autossómica dominante causada pela expansão de 
uma repetição do trinucleótido CAG no gene IT15 ou HD que codifica a proteína huntingtina (Htt). 
A repetição de CAG codifica um longo domínio de poliglutaminas nesta proteína, que se acredita 
conferir um ganho de função deletério. A característica mais importante da doença é a perda 
neuronal selectiva, principalmente dos medium spiny neurons do estriado, e no córtex cerebral, em 
fases mais avançadas da doença. A neurodegenerescência conduz a um défice motor, sendo os sinais 
clássicos da doença a coreia e distonia, descoordenação, e problemas comportamentais que 
conduzem à deterioração cognitiva progressiva. As disfunções metabólicas são relativamente 
comuns nesta doença, tais como a alteração no metabolismo da glucose, diabetes e alterações na 
sensibilidade/resistência à insulina. Vários estudos demonstraram que doentes com HD e murganhos 
transgénicos R6/2 (que expressam o exão 1 da huntingtina mutante, mHtt) possuem uma maior 
incidência de diabetes. No entanto, nada se sabe sobre o efeito da expressão da mHtt na disfunção 
metabólica periférica. Os murganhos YAC128 expressam mHtt completa com 128 glutaminas e 
manifestam um fenotipo próximo dos doentes com HD, incluindo alterações motoras precoces, 
declínio cognitivo e atrofia e degenerescência estriatal dependente da idade. Estes murganhos foram 
criados num background FVB, sendo mais susceptíveis à desregulação metabólica e resistência à 
insulina. Assim, o objectivo deste estudo foi avaliar o efeito da hiperglicémia em parâmetros 
metabólicos periféricos e centrais em murganhos YAC128 versus wild-type (WT), com a mesma 
idade. Os nossos resultados mostraram que os murganhos WT e YAC128 com 6 meses de idade são 
hiperglicémicos, apresentando glicemia de jejum acima de 130 mg glucose /dl sangue. A diabetes foi 
avaliada pelos testes de tolerância à glucose e insulina (GTT e ITT, respectivamente). Os murganhos 
YAC128 não apresentavam alterações significativas no peso corporal, nos níveis plasmáticos de 
glucose ou no GTT em comparação com os murganhos WT. Porém, no ITT os murganhos YAC128 
mostraram uma tendência para uma ligeira redução dos níveis de glucose no sangue após 30 minutos, 
o que poderá indicar alguma sensibilidade à insulina. No teste comportamental de rotarod os 
murganhos YAC128 demonstraram uma tendência para uma diminuição da latência para cair, 
sugerindo alguma deficiência motora em murganhos transgénicos, em comparação com os WT. Os 
níveis plasmáticos de IGF-1 e insulina apresentaram uma tendência para uma redução nos 
murganhos transgénicos relativamente aos murganhos WT. No cérebro, os níveis de IGF-1 
apresentaram uma ligeira tendência para uma diminuição nos animais YAC128, concomitante com 
uma redução na carga energética e um aumento da razão lactato/piruvato, sugerindo alterações 
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bioenergéticas neste modelo animais da HD. Os nossos dados sugerem fortemente que a expressão 
de mHtt em murganhos hiperglicémicos induz alterações metabólicas periféricas e centrais 
associadas com os níveis de insulina plasmática e com um metabolismo energético cerebral 
comprometido, que se correlaciona com um défice motor. Este estudo pode ser importante para 
definir o papel da mHtt na susceptibilidade dos doentes de Huntington para a desregulação 
metabólica e a ocorrência de diabetes. 
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Summary 
Huntington's disease (HD) is an autosomal dominant disease caused by an expansion of CAG 
repeats in the gene (IT15 or HD gene) encoding for huntingtin (Htt). The expanded repeat encodes a 
polyglutamine stretch that is believed to confer a deleterious gain-of-function to the protein. The 
most significant hallmark of HD is the selective neuronal loss, primarily in the striatum and in 
cerebral cortex in later stages. This neurodegeneration leads to progressive motor and cognitive 
deterioration, including chorea and dystonia, incoordination, psychiatric disturbances, cognitive 
decline and dementia. Metabolic dysfunction is relatively common in this disease and may be caused 
by impaired carbohydrate metabolism, diabetes and changes in insulin sensitivity. Several studies 
demonstrated that HD patients and the R6/2 HD transgenic mouse model (expressing the exon-1 of 
human Htt) show increased incidence of diabetes mellitus. However, nothing is known about the 
effect of expression of full-length mutant Htt (mHtt) on peripheral metabolic dysfunction. The 
YAC128 mice express full-length mHtt with 128 glutamines and manifest a phenotype close to HD 
patients, including early motor abnormalities, cognitive decline and age-dependent striatal atrophy 
and degeneration. These mice were created in a FVB background, known to be more susceptible to 
metabolic dysregulation and insulin resistance. Thus, the objective of our study was to evaluate the 
effect of an hyperglycemic background on peripheral and central metabolic parameters in YAC128 
mice versus age-matched wild-type (WT) littermates. Our results showed that 6 month-old YAC128 
and WT mice were hyperglycemic, exhibiting fasting plasma glucose levels over 130 mg/dl. 
Diabetes was evaluated by the glucose and insulin tolerance tests (GTT and ITT, respectively). 
YAC128 mice did not exhibit significant changes in body weight, plasma glucose levels or GTT 
compared to WT mice. However, in ITT YAC128 mice showed a tendency for a slight reduction in 
blood glucose levels at 30 minutes, which may indicate some sensitivity to insulin. The rotarod 
behaviour test showed that YAC128 mice had a tendency for decreased latency to fall off, suggesting 
some motor impairment in hyperglycemic HD mice, compared to WT littermates. In transgenic mice, 
plasma levels of IGF-1 and insulin were slightly, although not significantly, decreased. In brain, IGF-
1 levels showed a slight tendency for a reduction in YAC128 mice, concomitantly with a reduction 
in energy charge and higher lactate/pyruvate ratio, probably as a result of bioenergetic abnormalities 
in HD mice. Our data highly suggest that expression of full-length mHtt in hyperglycemic 
background induces both peripheral and central metabolic changes, which may result from altered 
plasma insulin levels, and deficient brain energy metabolism associated with motor impairment. This 
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study may be important for defining the role of mHtt in the susceptibility of HD patients to undergo 
metabolic deregulation and diabetic features. 
 
Part I 
1 
 
 
 
 
 
 
 
 
 
 
 
 
PART I 
 
GENERAL INTRODUCTION AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
Chapter I 
2 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER I 
 
GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
Chapter I 
3 
 
1.1. Huntington’s disease 
Huntington‘s disease (HD) is a fatal neurodegenerative disorder that was first described by 
George Huntington in 1872. He published his report on a hereditary form of chorea in The Medical 
and Surgical Reporter (Huntington, 1872). 
 
In his writing, he describes the disease in an accurate way, referring “three marked 
peculiarities in this disease:  
1. Its hereditary nature.  
2. A tendency to insanity and suicide. 
3. Its manifesting itself as a grave disease only in adult life” 
 
 
Despite Mendel‘s Laws describing the principle of hereditary transmission were still recent and 
weakly disseminated, Huntington was able to note the autosomal dominant inheritance: 
“The hereditary chorea, as I shall call it, is confined to certain and fortunately a few 
families, and has been transmitted to them, an heirloom from generations away back in 
the dim past.……. When either or both the parents have shown manifestations of the 
disease, and more especially when these manifestations have been of a serious nature, 
one or more of the offspring almost invariably suffer from the disease, if they live to adult 
age. But if by any chance these children go through life without it, the thread is broken 
and the grandchildren and great-grandchildren of the original shakers may rest assured 
that they are free from the disease.” 
 
 
The average onset is about 40 years, ranging from 1 to 80 years (Nance et al., 2001;for review, 
Walker, 2007), progressing inexorably to death 15-20 years after the onset (for review, Rego et al., 
2005). Only about 5-7% of patients exhibit symptoms before 21 years-old, in what was defined as 
the juvenile form of HD (Nance et al., 2001).  
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In early stages of the disease there are subtle psychiatric changes that are often 
misunderstood, since they are not severe enough to be recognized on their own. HD is associated 
with movement disorder (also named chorea) which becomes worse over the course of disease, but 
also involves emotional and cognitive disturbances, leading to dementia, as described in section 
1.1.3.  
 
1.1.1. Epidemiology 
HD is one of the most important genetic disorders of adulthood.  
Europe has the largest number of prevalence studies and, as it can be seen in Figure 1.1., an 
uniform prevalence of HD. Indeed, a prevalence of 4-7 per 100,000 people is found over a large part 
of the continent. Finland reveals an atypical low prevalence, of about 0.5 per 100,000 individuals, 
which can be related to genetically distinct features from other populations, probably diverged from 
the common origin before such mutations occurred (Harper, 1992). A previous study in South Wales 
found a prevalence of 8.85 HD cases per 100,000 people (Quarrell, 1988). 
 
 
Table I. Prevalence estimates for HD in 
Europe (excluding UK) 
 
Based on Harper (1992) 
Fig. 1.1. HD prevalence in various 
European countries. There is a high 
prevalence rate for HD in most European 
countries where it has been intensively 
studied; Finland is an exception [Harper, 
1992]. 
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HD was originally described in North America, in families of British descent, as confirmed 
by the elevated rate of occurrence in descendents of Western European. In 2000, there were 30,000 
cases of HD in United States, indicating a prevalence of about 10 cases per 100,000 people. The 
prevalence of HD in African Americans generates some controversy. Some studies described a much 
lower rate (Wright et al., 1981), but this number was refuted by the Maryland study, which found a 
prevalence of 5.15 per 100,000 people, based on a population of 4,217,000, a similar number to the 
population of Western-European origin. In most of these affected families, the HD allele did not 
have an European origin (Folstein et al., 1987). 
In Portugal. the prevalence of HD is estimated to range from 2-5 per 100,000 people, 
overlapping the european values (Costa et al., 2003). 
The disorder is rare in Orientals and Africans, suggesting that HD gene is rare (Harper, 1992). 
Japan has a very low rate, of about 0.5 per 100,000 people (Walker, 2007). In contrast, there are 
some regions where the prevalence is unusually high. Some studies were able to track the ancestor 
by genealogical analysis, mainly due to historical migration and geographic isolation of these areas. 
Tasmania has a prevalence of 17,4/100,000 people and the region of Lake Maracaibo, Venezuela, 
has more than 100 living HD patients, all descended from a single ancestor (Conneally, 1984; 
Harper, 1992). Importantly, HD affects equally males and females. The total heterozygote frequency 
in South Wales has been estimated at 20.2 per 100,000 people (Conneally, 1984). 
 
1.1.2. Genetics  
An expansion of cytosine-adenine-guanine (CAG) repeats was first described in the androgen 
gene, and since then a class of nine genetically distinct, gain-of-function disorders were described, 
constituting the polyglutamine-expansion diseases. These include HD, dentatorubralpallidoluysian 
atrophy, spinal bulbar muscular atrophy (SBMA) or Kennedy‘s disease  and spinocerebellar ataxias 
1, 2, 3, 6, 7 and 17 (Table II) (Bates, 2005). 
The gene affected in HD encodes the protein huntingtin (Htt) and the mutation results in a 
stretch of glutamine residues located at the N-terminal of mutant Htt (mHtt) (The Huntington's 
Disease Collaborative Research Group, 1993). This is believed to confer a deleterious gain-of-
function to the mutant protein. The HD gene was mapped in 1983 with the eight polymorphic marker 
test (G8), which mapped the gene to chromosome 4 (4p) (Gusella et al., 1983). However, the HD 
gene was cloned only in 1993, which allowed the identification of a coding region occurring at the 
short arm of chromosome 4 (4p16.3), corresponding to an unstable DNA segment containing an 
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expansion of a polymorphic trinucleotide repeat, near the 5‘ end in the exon 1 of the “Interesting 
Transcript 15” (IT15) gene, that spans over 200 kb and is composed of 67 exons (The Huntington's 
Disease Collaborative Research Group, 1993). 
 
Table II Polyglutamine Expansion Diseases 
Polyglutamine 
disorder CAG 
Protein product/ 
Locus 
Normal and 
Pathogenic 
repeat number 
Primary target of 
neuropathology 
Dentatorubro-
pallidoluysian atrophy 
(DRPLA) 
Atrophin 1 
12p12 
3-35 
49-88 
Cerebellum (dentate nucleus), red 
nucleus, globus pallidus (external 
segment), subthalamic nucleus 
Huntington‘s disease (HD) 
Huntingtin 
4p16.3 
6-35 
36-121 
Caudate nucleus (medium spiny 
neurons), putamen, globus pallidus 
(external segment) 
Spinal and bulbar muscular 
atrophy (SBMA;Kennedy 
disease) 
Androgen receptor 
Xq11-q12 
9-36 
38-62 
Motor neuron in anterior horn 
cells of the spinal cord and 
brainstem 
Spinocerebellar ataxia 1 
(SCA1) 
Ataxin 1 
6p23 
6-38 
39-83 
Cerebellum, red nucleus, inferior 
olive, pons,anterior horn cells and 
pyramidal tracts 
Spinocerebellar ataxia 2 
(SCA2) 
Ataxin 2 
12q24 
14-31 
32-77 
Cerebellar Purkinje cells, 
cytoplasmatic inclusions 
Spinocerebellar ataxia 3 
(SCA3) 
Ataxin 3 
14q24.3-q31 
12-40 
54-86 
Cerebellar dentate neurons, basal 
ganglia, brain stem, spinal cord 
Spinocerebellar ataxia 6 
(SCA6) 
Ca2+channel 
19p13 
4-19 
20-30 
Cerebellar Purkinje cells, dentate 
nucleus, inferior olive, 
cytoplasmatic inclusions 
Spinocerebellar ataxia 7 
(SCA7) 
Ataxin 7 
3p21.1-p12 
4-35 
37-200 
Cerebellum, brain stem, macula, 
visual cortex 
Spinocerebellar ataxia 17 
(SCA17) 
TATA-binding 
protein (TBP) 
6q27 
29-42 
47-55 
Cerebellum, cortex (diffuse 
atrophy), caudate and putamen. 
NII 
Based on Rego and de Almeida, 2005. 
 
Normal alleles are defined as alleles with < 26 CAG repeats; these are non-pathologic and 
segregated as a stable polymorphic repeat in > 99% of meiosis. In normal individuals, the most 
frequent allele length contains 17 and 19 CAG repeats (Kremer et al., 1994) 
Mutable normal alleles are defined as alleles with 27-35 CAG repeats. This repeat range is 
often referred to as the meiotic instability range or as "intermediate alleles". No case has been 
associated unequivocally with an HD phenotype (Rubinsztein et al., 1996, Brinkman et al., 1997), 
but they can be meiotically unstable in sperm, and predispose to CAGs expansion from one 
generation to the next, particularly when the disease is transmitted by males (Myers et al. 1993; 
Rubinsztein et al., 1996). This susceptibility was only described during transmission through the 
male germline and is associated with advanced paternal age (Goldberg et al., 1993).  
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HD alleles with reduced penetrance are defined as having 36-39 CAG repeats; these are 
meiotically unstable and associated with HD phenotype in both clinically and neuropathologically 
documented cases (Nance et al., 2001). Few asymptomatic individuals over 75 years, with this allele 
size, have been documented (Rubinsztein et al., 1996). 
Alleles with > 40 CAG repeats are defined as alleles with full penetrance. While there are 
several reports of elderly clinically asymptomatic HD gene carriers with 40 and 41 CAG repeats, no 
individuals with >41 CAG repeat length remained asymptomatic after middle life and the probability 
of an earlier onset is inversely related to number of CAG repeats (Brinkman et al., 1997). The 
presence of ≥ 60 CAGs is associated with juvenile onset that represents approximately 5-7% of all 
cases (Nance, 2001). A few cases of juvenile-onset disease with more than 200 CAG repeats have 
been documented (Nance et al., 1999; Seneca et al., 2004) (Figure 1.2.) 
 
 
 
Fig. 1.2. Representation of the HD gene and the impact of polyglutamine repeat size on HD onset 
[Adapted from Rego and de Almeida, 2005] 
 
 
As an autosomic dominant disorder, the HD offspring have 50% chance of inheriting the 
disease in a Mendelian mode.  
The number of polyglutamines is inversely correlated with age of onset (Duyao, 1993, 
Nørremølle, 1993), but this only accounts for about 40% of the variation, with the remaining due to 
genetic polymorphisms adjacent to CAG repeat (for review, Rego and Almeida, 2005) and 
environment (Wexler, 2004). However, some studies did not find a relationship
 
between the number 
of CAG repeats and the rate of clinical decline (Kieburtz, 1994), which suggested that CAG repeat 
length may have a small effect on the rate of
 
progression that may be clinically important over time 
(Rosenblatt, 2006). 
A large population sample was analyzed in Portugal, showing that CAG ranged between 9 
and 40 repeats, with the 17 CAG allele occurring most frequently (37.9%). Intermediate alleles with 
Chapter I 
8 
 
27–35 CAGs represented 3.0% and two expanded alleles (0.11%) were found, one of reduced 
penetrance (36 CAGs) and other with fully penetrant repeat (40 CAGs) (Costa et al., 2006). 
The number of CAG repeats is only highly predictive of the age of onset if CAG≥ 40. The 
genes encoding for NR2A/B receptor subunits of the N-methyl-D-aspartate (NMDAR) receptor may 
be responsible for the variance on the age of onset in individuals with CAG repeat lengths between 
30-40 (Arning et al., 2005). In a cohort of HD patients with a CAG repeat length between 41 and 45, 
30.8% of the variance in age of onset could be attributed to CAG repeat number, while variations in 
the NR2A (N-methyl-D-aspartate receptor receptor subunit) and NR2B genes accounted for 4.5% 
and 12.3% of the variance, respectively (Arning et al., 2005) 
 
1.1.3. Clinical aspects 
HD symptoms typically manifest in midlife, between 35-50 years old and become fatal 15-20 
years after the onset and juvenile or late-onset forms have shorter disease (Foroud et al., 1999) 
(Figure 1.3.). 
 
 
 
Fig. 1.3. Survival curves. The mean illness duration is higher for the second group (20-34 years old) and 
significantly shorter among juvenile (< 20 years old) and late onset patients (> 50 years old, having this two 
groups a similar duration (Foroud et al., 1999). 
 
Psychiatric and behavioral problems usually appear early in the course of the disease and are 
major constituents of the clinical spectrum of HD (Duijn et al., 2007).The disease it‘s classically 
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Fig. 1.4. EMG recording of chorea in a patient in stage I HD. 
Recording is made with standard belly tendon, using surface disc electrodes placed over the 
first dorsal interosseus muscle. Graph presents an irregular pattern of discharges, with 
variable amplitude, duration, and rise times of every EMG burst. Healthy individuals at rest 
show no EMG activity (Walker, 2007). 
 
associated with progressive emotional, cognitive, and motor disturbances. In a presymptomatic phase 
(prodromal phase), relatively subtle symptoms (e.g. changes in personality, cognition, and motor 
control) may precede the disease onset by several years. Irritability or disinhibition, difficulty in 
developing multitasking, forgetfulness and anxiety are common, depression, impulsiveness, apathy 
and also motor changes including minor difficulties in coordination, balance, and slight adventitious 
movements of the trunk, limbs, and finger can be present (for review, Walker, 2007; Foroud et al., 
1999). Oculomotor abnormalities are primordial features and often the earliest motor sign; delayed 
initiation and slowing of saccadic movements, and inability to suppress glances at novel stimuli and 
an occasional nystagmus (Leigh et al., 1983). 
One of the most characteristic sign of HD is both involuntary and voluntary movement 
disorders. Involuntary movements were first described by George Huntington as Chorea, derived 
from the Greek word χορεία (a kind of dance). Choreoathetotic movements are clonic spasm 
affecting voluntary muscles, with a random pattern. The severity varies from restlessness with mild, 
intermittent exaggeration of gesture and expression, through fidgety movements of hands and 
unstable dance-like gait, to a continuous flow of disabling and violent movements (Wild et al., 
2007). Motor symptoms commonly begin by slight twitchings in the muscles of the face, which 
gradually increase in violence and variety, which may interfere with vocalization, chewing and 
swallowing. Dysarthria and dysphagia are common in these patients (for review, Walker, 2007). 
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Voluntary movements are also disturbed, leading to bradykinesia and rigidity with slow 
initiation and poor execution of coordinated movements, especially in later stages of the disease 
(Purdon et al., 1994). In children with the juvenile form, a dominant picture of bradykinesia, rigidity, 
dystonia, ataxia and epileptic seizures occurs (Seneca et al., 2004; Ruocco et al., 2006). Another 
finding in HD that contributes to patients‘ overactivity is motor ‗impersistence‘ — the inability to 
maintain a voluntary muscle contraction at a constant level. In Figure 1.4. an electromyography 
(EMG) (recording of electrical activity of skeletal muscle) recording of chorea in patient with stage I 
HD shows a variable and random patterns of muscle activation with short duration bursts common in 
HD. Incapacity to apply steady pressure during handshake is characteristic of HD and is called 
milkmaid’s grip. Motor ‗impersistence‘ is a good marker of disease severity, since it is independent 
of chorea and linearly progressive. Fine motor skills, such as finger-tapping rhythm and rate, are 
useful for establishing an early diagnosis of HD (Walker, 2007). Although chorea is the cardinal 
feature of HD, a significant percentage of patients do not refer it as the first symptom; rather, the 
patients refer other prominent symptoms, like cognitive or emotional changes (Foroud et al., 1999). 
 
 
Table III – First symptoms of HD  
 
Number of patients is reported from a total of 1901 patients 
with initial symptom information. Percentage of all observed 
symptoms from a total of 3086 reported symptoms. Patients 
could report up to three initial symptoms (Foroud et al., 1999). 
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Several studies showed a high frequency of psychiatric disturbances in HD (Table III). 
Depressive symptoms could be a direct result of brain degeneration or a psychological reaction to the 
disease. Affective component is a major concern given the high risk of suicide, estimated to be 5-10 
times more frequent than in general population (Duijn et al., 2007; for review Walker, 2007). 
As disease progresses, memory deficits tend to appear. Reported impairments range from 
short-term memory deficits to long-term memory difficulties, including deficits in procedural and 
working memory. Cognitive problems tend to get worse over time and, in late-stage HD, leads to 
dementia (Montoya et al., 2006). 
Sleep disturbances are also common clinical problems in HD and include increased sleep 
onset latency, reduced sleep efficiency, disruption of sleep, more time spent awake and less slow 
wave sleep. These abnormalities appear to be related with duration and severity of the disease, and 
degree of atrophy of the caudate nucleus. Patients also show an increased density of sleep spindles 
(Wiegand et al., 1991, Hansotia et al., 1995, Cuturic et al., 2009). Recently, it was shown that HD 
patients have a disrupted circadian rhythm (Morton et al., 2005) probably due to melatonin 
deficiency (Alders et al., 2009). 
Interestingly, the most frequent primary cause of death in HD is pneumonia and 
cardiovascular disease (Sǿrensen et al., 1992). 
 
 
1.1.4. Neuropathology 
Basal ganglia are a group of nuclei located subcortically that are involved in motor and 
cognitive processes. Cerebral cortex and substantia nigra pars compacta (SNpc) send glutamatergic 
and dopaminergic inputs, respectively, to caudate and putamen, and frontal cortex receives 
transiently excitatory input from the thalamus (Purves et al., 2004). Connections between basal 
ganglia output nuclei (GPi/SNr) (globus pallidus interna/ substancia nigra pars reticulata) and 
striatum are organized in two pathways: direct and indirect.  
The direct pathway is a ―monosynaptic‖ transiently inhibitory projection between medium 
spiny neurons (MSN) of caudate and putamen to the tonically active inhibitory neurons in GPi/SNr, 
which in turn provides inhibitory innervation to thalamocortical projections (ventral anterior and 
ventral lateral thalamic nuclei - VA/VL complex).  
The indirect pathway is a ―polysynaptic‖ connection that involves intercalated neurons in 
globus pallidus externa (GPe) and STN (subthalamic nucleus) and increases the level of tonic 
(MSN) 
Chapter I 
12 
 
inhibition. Ninety-five per cent of all neurons in striatum are GABAergic and contain mainly the 
inhibitory neurotransmitter γ-aminobutyric acid (GABA) and enkephalin, dynorphin or substance P 
(SP) as co-transmitter. When the indirect pathway is activated by excitatory signals from the cortex, 
MSN discharge and inhibit tonically active GABAergic neurons of GPe. These neurons project to 
STN, which in turn sends excitatory inputs to GPi and SNpr that oppose the disinhibitory action of 
the direct pathway. Thus, indirect pathway modulates the direct pathway. Most MSNs express D1 
(subtype 1 dopamine receptor) and D2 (subtype 2 dopamine receptor) receptors, the majority of D1-
expressing neurons being part of direct pathway and containing substance P, whereas D2- bearing 
neurons are part of indirect pathway, projecting to GPe and contain enkephalin (Purves et al., 2004). 
SNr also projects its axons to deep layers of superior colliculus, an area of the upper motor 
neurons that command the saccades (rapid orienting movements of the eyes). Immediately before 
saccade onset, discharge rate of reticulata neurons is greatly reduced through the input from tonic 
GABAergic MSNs of caudate, which have been activated by signals from cortex. As a consequence 
upper motor neurons of superior colliculus is activated, allowing them to generate bursts of action 
potentials that command the saccade (Purves et al., 2004). 
In patients with HD, MSN that project to the external segment of GP degenerate, especially 
those synthesizing enkephalin and GABA. In absence of their normal inhibitory input from spiny 
neurons, GPe cells become abnormally active; in turn, this activity reduces the excitatory output of 
STN to GPi, leading to the reduction of the inhibitory outflow of the basal ganglia (Figure 1.5.), 
(Purves et al., 2004). 
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Fig.1.5. Direct and indirect pathways through basal ganglia in HD. The balance of inhibitory signals in 
direct and indirect pathways is altered, leading to a decrease ability of basal ganglia to control the thalamic 
output to cortex. Projection from caudate and putamen to GPe is decrease (thinner arrow). This effect 
increases the tonic inhibition from GP to STN (larger arrow), making the excitatory STN less effective in 
opposing the action of direct pathway (thinner arrow). Thus, thalamic excitation of cortex is increased (larger 
arrow), leading to greater and often inappropriate motor activity. VA -ventral anterior thalamic nuclei; VL- 
ventral lateral thalamic nuclei (Purves et al., 2004). 
 
 
Without the restricting influence of basal ganglia, upper motor neurons can be activated by 
inappropriate signals, resulting in choreatic movements and slowing of saccadic movements(Purves 
et al., 2004). 
As mentioned before, basal ganglia are also involved in other non-motor functions with 
significant clinical implications. Degeneration of specific subdivisions of prefrontal and limbic loop 
appears to be related with deterioration of cognitive and emotional function typical in HD (Purves et 
al., 2004). The prefrontal loop regulates the initiation and termination of cognitive processes (e.g. 
planning, working memory and attention) and the limbic loop regulates emotional behavior and 
motivation (Purves et al., 2004). 
Degeneration can be found at different degrees in MSNs. In early and middle stage HD, 
enkephalinergic striato-GPe projection and SP-containing projection to SNr (indirect pathway) are 
more severely affected than SP -containing projections to the GPi and SN (direct pathway), resulting 
in an imbalance between the direct and indirect pathways. A possible explanation is that SP-
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containing striato-SNr neurons and enkephalin-containing striato-GPe neurons are lost at a greater 
rate than either SP-containing striato-SNc or SP-containing striato-GPi neurons. In end-stage HD, all 
classes of striatal projection neurons are affected (including striate-GPi) which may explain the 
bradykinesia and rigidity (Reiner et al., 1988; Deng et al., 2004). In HD, glutamic acid 
decarboxylase (GAD), the enzyme that is involved in GABA synthesis, is significantly decreased in 
GPe but not in GPi in early stages, whilst in grade 4 patients the GAD fiber depletion from both 
structures was much larger. (Deng et al., 2004) 
Striatal projecting neurons and parvalbuminergic striatal interneurons degenerate during HD 
(Harrington and Kowall, 1991; Vonsattel and DiFiglia, 1998), whereas cholinergic striatal 
interneurons and striatal interneurons containing somatostatin, neuropeptide Y and/or NADPH 
diaphorase (or nitric oxide synthase) and medium-sized calretinergic striatal interneurons survive in 
the pathology (Ferrante et al., 1985, 1986, 1987; Fusco et al., 1999, Cicchetti et al., 2000). Multiple 
factors contribute to this selective vulnerability including: differential expression of Htt, changes in 
innervations, the extent of input from cortical or any other huntingtin-rich glutamatergic neurons or 
the extent to which this neurons possess certain types of glutamate receptors (Fusco et al., 1999). 
Reactive astrocytosis (gliosis) is also a common find together with neuronal loss. Other areas 
of basal ganglia (especially GP and STN) also become atrophic, though less than striatum (Ross et 
al., 2001). 
A 0-4 rating scale (the `Vonsattel scale') of gross and microscopic neurodegeneration, based 
primarily on changes in caudate and putamen (e.g. Figure 1.6.), has been used to semi-quantitatively 
describe the severity of HD. Grade 0 appears indistinguishable from normal brains after gross 
examination. However, 30–40% neuronal loss can be detected in the head of caudate nucleus upon 
histological examination. Grade 1 shows atrophy in the tail and in some cases the body of caudate 
nucleus. Neuronal loss and astrogliosis are evident in the head (50% loss), tail and, to a lesser extent, 
in the body of caudate nucleus. Grade 2 is associated with gross striatal atrophy that is more 
pronounced than that detected in grade 1 brain. Grade 3 displays severe gross striatal atrophy. 
Grade 4 includes HD cases with severe atrophy of striatum and up to 95% neuronal loss (Vonsattel 
et al., 1985, Gil et al., 2008). 
More severe neurodegeneration in caudate and putamen were associated with longer 
expanded repeat nucleotide, which is associated with a faster deterioration and greater pathological 
severity (Furtado et al., 1996).However, the degree of tissue atrophy may not be solely determined 
by the primary genetic abnormality (Sieradzan et al., 1997). 
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In advanced cases, total brain weight is reduced by 25-30% (Margolis et al., 2003). 
 
 
  
 
 
 
 
 
 
Hypothalamus is a region of the brain involved in regulation of metabolism and sleep, and 
includes the pituitary gland that regulates hormonal levels in the body. A substantial trophy and cell 
death has been described in hypothalamus from HD patients (Kremer et al., 1990). Cells more 
severely affected are located in the lateral tuberal nucleus (nucleus tuberalis lateralis, NTL) of 
hypothalamus. In NTL of HD patients, about 90% neuronal loss was found and the remaining 
neurons showed features of degeneration (Kremer et al., 1990). There was also astrocytosis and 
reduction of 40% in the number of oligodendrocytes (Kremer et al., 1990). This NTL vulnerability 
appears to be related to the high density of NMDA receptors in this nucleus (Timmers et al., 1996). 
There is also a significant loss of orexin-containing neurons in hypothalamus (Petersen et al., 2005)  
 
1.1.4.1. . Formation of aggregates 
Htt is a protein wih approximately 350 kDa, composed of more than 3100 aminoacids (aa). It 
is primarily a cytosolic protein, ubiquitously expressed in mammalian tissues, including brain 
Fig. 1.6. Macroscopic image of a slice of Huntington's brain (left) and from a 
normal control (right). Note that striatum (caudate nucleus, putamen, and nucleus 
accumbens) and also cerebral cortex, on the left, are severely atrophied in  
Huntington's brain. Photo from the Harvard Brain Tissue Resource Center. 
Adapted from Http://hdroster.iu.edu/AboutHD/brainAndHD.asp  
Chapter I 
16 
 
(Trottier et al.,1995). Cellular functions of Htt remains unclear, however it has been associated with 
the nucleus, endoplasmic reticulum, Golgi complex, synaptic vesicles and mitochondria (Li and Li, 
2004). Some studies suggested that it has an important role during embryogenesis, being essential for 
gastrulation. Knockout of the gene in mouse during embryonic stage was lethal approximately at day 
7.5, whilst the conditional knockout in mouse forebrain at postnatal or later embryonic stages causes 
a progressive neurodegenerative phenotype, suggesting a constitutive role important for neuron 
survival (for review, Bhide et al., 2006). Htt was also detected through human brain from 19
th
 to 21
st
 
week of fetal gestation, suggesting that it may play an important constitutive role in neurons during 
brain development. This also suggests that the development controls heterogeneity in neuronal 
expression of Htt and that intraneuronal distribution of the protein may be directly correlated with 
neuronal maturation (for review, Bhide et al., 2006). Transiently knockdown of endogenous Htt by 
morpholino oligonucleotides in zebrafish revealed that it may be essential to development and it may 
be involved in normal blood function and iron utilization (Lumsden et al., 2007). Furthermore, Htt 
appears to be important during adult life. In this regard, delection of Htt gene in Drosophila showed 
that it may have an essential role in long-term mobility and survival of adult animals, accelerating 
the neurodegenerative phenotype (Zhang et al., 2009). Additionally, the conditional deletion of Htt 
in forebrain and testis of adult mice led to degeneration of these tissues (Li and Li, 2004). 
Htt interacts with a wide range of cellular proteins through multiple interaction domains. 
Structural analysis of Htt identified up to 36 HEAT (huntingtin, elongation factor 3, the A subunit of 
protein phosphatase 2A and TOR1) repeats, with approximately 40-amino acid long, composed of 
two hydrophobic antiparallel helices that acts as a scaffold protein. 
Proposed cellular functions of Htt include endocytosis, modulation of synapse structure and 
synaptic transmission; transcriptional regulation (especially of brain-derived neurotrophic factor 
(BDNF), essential for survival of striatal neurons in HD; axonal transport of BDNF and vesicles, and 
anti-apoptotic activity (Ho et al., 2001, Leavit et al., 2001, Leavit et al., 2006, Caviston and Holbaur, 
2009). 
HD pathogenesis has been suggested to be also related with a loss of function in wild-type 
Htt. This may be due to a 50% decrease in the expression of Htt and to its cleavage and sequestration 
into aggregates, thus impairing its neuroprotective function and culminating in neuronal dysfunction 
and death (Ho et al., 2001). The polyglutamine repeat (polyQ) expansion promotes association with 
several proteins, leading to their intracellular accumulation into 5-7 μm aggregates. Formation of 
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such aggregates could indicate either an inability to degrade the mHtt or an overall inhibition of 
cellular trafficking and degradation machinery (Figure 1.7.) (Gatchel and Zoghbi, 2005). 
 
 
 
Two mechanisms have been hypothesized for aggregate formation of aggregates: 
- the Polar zippers model refers that aggregation results from multimerization by 
hydrogen‑bonded polar zipper. This was confirmed by the reduction of to monomeric fragments 
upon incubation in concentrated formic acid (Perutz et al., 1994). The 40 residues threshold of polyQ 
has been explained by the fact that the protein sequence forms a helical fiber with 20 residues turn, 
and that two turns (40 residues) are required for stabilization of the helix and promotion of 
multimerization (for review, Hoffner et al., 2007);  
 - Transglutaminase‑catalyzed cross‑linking. Transglutaminases are enzymes involved in 
cross-linking of glutamine residues and, thus, may also participate in the formation of aggregates. 
Several in vitro studies showed that depending on protein length Htt is a substrate of 
transglutaminase (Kahlem et al., 1998). Transglutaminase activity appers to be elevated in HD brain 
cortex and cerebellum, regions where Htt aggregates into nuclear inclusions (Karpuj et al., 1999). A 
possible function of brain transglutaminase is stabilization of neuronal aggregates. This is 
corroborated by its wide distribution and activation in brain and by the occurrence of ε- (γ-glutamyl) 
lysine cross-linking in normal brain (Karpuj et al., 1999, Hoffener et al., 2007, for review, Gil and 
Rego, 2008). 
Inclusions were found in affected areas of brain (such as cortex and caudate/putamen) but not 
in unaffected areas (such as cerebellum) (Hoffner et al., 2005). Interestingly inclusions observed in 
Fig. 1.7. Normal and aberrant form of polyglutamine protein. Hypothetical abnormal 
interactions, where some might be inappropriately enhanced and others might be lost or 
unchanged. [Adapted from Gatchel and Zoghbi, 2005] 
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affected areas are limited to neurons and are not detected in glial cells (Hoffner et al., 2005). In 
juveline form of disease, with large polyQ expansion, inclusion tend to be located in nucleous whilst 
in patients with the adult onset HD patients (with shorten polyQ expansion) inclusions are mostly 
cytoplasmatic (DiFiglia et al., 1997).  
A study using an antibody directed against the 17 most N-terminal amino acids of Htt, 
showed that the frequency of nuclear inclusions (but not that of cytoplasmic inclusions) is correlated 
with the severity of disease, suggesting that nuclear aggregation (but not cytoplasmic aggregation) 
might participate in neuronal death (Hoffner et al., 2005). Another study identified others aggregates 
located in neuropils, which are likely to correspond to dendrites, and that may contribute to neuronal 
death, by disturbing dendritic transport (Gutekunst et al., 1999). 
Several studies demonstrated that Htt fragments are more toxic to cells than full-length mHtt 
and that such toxicity is proportional to the size of polyQ tract, being also related to the progressive 
truncation of Htt (Thakur et al, 2009). A consequence of Htt cleavage is the release of N-terminal 
fragments (Htt
NT
) containing the polyQ tract, which interacts with at least 25 proteins that can be 
recruited into aggregates of mHtt (Wellington et al., 2003).  
 
 
 
 
In affected areas of the brain (such as cortex) normal Htt exists as a soluble monomer, but the 
mHtt is found in fragmented, oligomerized and polymerized forms, which can be either soluble or 
insoluble in water. The water-soluble forms of cortical mHtt consist of oligomerized and fragmented 
Htt. Soluble oligomers appear to accumulate in cortex, where they are much more abundant than the 
normal protein. The water-insoluble mHtt, which is mostly associated with inclusions, consists of 
oligomeric, polymeric and fragmented protein, establishing bonds with each other via non-covalent 
Fig. 1.8. Mechanism of Htt fragments mediated exon1 aggregation. The Htt N-
terminal (Htt
NT
) (green) unfolds in a polyQ repeat length dependent fashion and, once 
unfolded, self-aggregates without a nucleation barrier to form oligomers with cores 
comprised of Htt
NT
 and not polyQ (red). Final aggregates are rich in β-sheet, are fibrillar, 
and involve both Htt
NT
 and polyQ. [Adapted from Thakur at al, 2009]. 
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bonds since they are released by formic acid. These structures are stabilized by covalent bonds since 
presents resistant to formic acid (Hoffner et al., 2007). Some evidences have shown that this 
inclusions could act as neuroprotective through sequestration of toxic N-terminal fragments and 
oligomers of mHtt and other misfolded proteins, which would be deleterious in the soluble form 
(Figure 1.8.) (for review, Gil and Rego, 2008). 
Accumulation of unfolded or misfolded proteins in endoplasmic reticulum (ER) could induce 
stress and trigger neuronal death. The apoptosis signal-regulating kinase 1 (Ask1), a MAPK kinase 
kinase that activates JNK pathway (c-Jun N-terminal kinases), may play a role in this process, since 
Ask1 is activated by ER stress and that phosphorylated Ask1 interacts with Htt fragments, allowing 
them to translocate into nucleus more efficiently. This interaction has a positive feedback loop, since 
it amplifies ER stress and may contribute to potentiate Htt toxicity (Cho et al., 2009).  
Activity of wild-type and mHtt can be modulated by post –translational modifications. MHtt 
can change post-tradutional modifications of proteins once they are formed. Several studies indicated 
that Htt phosphorylation at various sites is neuroprotective, by preventing cleavage of mHtt and its 
consequent aggregation. Activation of insulin growth factor 1 (IGF-1)/protein kinase B (Akt) 
pathway is protective for neurons expressing mHtt, probably due to phosphorylation of Htt on 
Ser421 (serine 421) (Colin et al., 2008).  
 
1.1.4.2. Intracellular mechanisms of toxicity  
The gain of function of mHtt and the loss of function of wild-type Htt are potential 
contributors to neuronal dysfunction in HD (for review, Landles and Bates, 2004). Several processes 
may be involved this deregulation, as described in Figure 1.9.: 
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Fig. 1.9. Model for cellular pathogenesis in Huntington’s disease. 1 - Molecular chaperones Hsp70 and 
Hsp40 promote folding of newly synthesized Htt into a native structure. Htt may be transported into nucleus 
and affect transcriptional regulation. Chaperones can facilitate the recognition of abnormal proteins, promoting 
either their refolding, or ubiquitination (Ub) and subsequent degradation by the 26S proteasome. 2- HD 
mutation induces conformational changes and is likely to cause abnormal folding of Htt, which, if not corrected 
by chaperones, leads to accumulation of misfolded Htt in the cytoplasm. 3- mHtt may also be proteolytically 
cleaved, resulting in amino-terminal fragments that form β-sheet structures. 4- toxicity may be elicited by m 
full-length Htt or by cleaved N-terminal fragments, which may form soluble monomers, oligomers or large 
insoluble aggregates. In cytoplasm m forms of Htt may impair the ubiquitin–proteasome system (UPS), leading 
to accumulation of more proteins that are misfolded. 5- These toxic proteins may also impair normal vesicle 
transport and clathrin-mediated endocytosis. Also, the presence of mHtt can activate proapoptotic proteins 
(directly or indirectly by mitochondrial damage), exacerbating cellular toxicity and other deleterious effects. 6- 
In an effort to protect itself, the cell accumulates toxic fragments into ubiquitinated cytoplasmic perinuclear 
aggregates. 7- In addition, mHtt can be translocated into nucleus to form nuclear inclusions, which may disrupt 
transcription and UPS [Adapted from Landles and Bates, 2004] 
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I. Protein misfolded and inhibition of protein degradation 
Formation of aggregates in nucleus, cytoplasm and neurons all processes is one of the main 
features of HD, involving sequestration of several proteins by N-terminal fragments of mHtt (for 
review, Landles and Bates, 2004) Several components involved in handling and degradation of 
misfolded proteins (e.g. chaperones, ubiquitin, proteasome subunits and autophagy proteins) were 
found on such aggregates (Mitra et al., 2009). Heat shock proteins (HSPs) may play an essential role 
in folding and assembly of newly synthesized proteins and in re-folding the misfolded ones and 
aggregation. HSP70, a molecular chaperone, is thought to bind in early stage of HD in order to 
maintain the protein in a soluble conformation. HSP 70 interacts with a co-chaperone protein that 
regulates its ATPase activity, the HSP 40 family. These chaperones also bind to misfolded proteins 
and are able to refold alone (Jana et al., 2000). Chaperones can also re-direct these proteins to the 
ubiquitin-proteasone pathway and increase the expression of HSPs, which has proven to be 
neuroprotective. These two chaperones were found in cytoplasmic and nuclear aggregates, probably 
as an attempt to refold the m protein (Jana et al., 2000). Chaperones were also reported to inhibit 
caspase-3 and 9 activities and to improve cell viability independently of aggregate formation (Zhou 
et al., 2001).  
mHtt was shown to interact with numerous transcriptional factors, such as NF-Y, which has 
been reported to regulate HSP70 transcription, resulting in an overall reduction of HSP 70 gene 
expression (Yamanaka et al., 2008).  
The ubiquitin-proteosome system (UPS) is another neuroprotective mechanism that prevents 
accumulation of misfolded proteins, by degrading them. In vivo studies have shown that UPS activity 
is impaired and some components of proteosome are sequestered into aggregates (Wang et al., 
2008). MHtt can be ubiquitinated, itself, which may represent an attempt to eliminate the aggregates 
(Mitra and Finkbeiner, 2008). However, several hypotheses have been proposed to explain such 
impairment: 1) mHtt could be retained in proteolytic core and impair proteasome activity; 2) mHtt 
aggregation may impair proteasome or 3) for the proteasome regulatory complex to unfold mHtt and 
present it to the core catalytic subunits for proteolysis (Mitra and Finkbeiner, 2008). In this regard, it 
has been suggested that HD could be a proteasomal storage disease (Goellner and Rechsteiner, 
2003).  
A recent study used mass-spectrometry-based methods to quantify polyubiquitin chains from 
transgenic mouse and knock-in models demonstrating that the abundance of lysine 48-linked 
polyubiquitin chains could be a faithful endogenous biomarker of UPS function (Bennett et al., 
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2007). These chains where shown to accumulate early in brains of mice and humans with HD 
showing that UPS dysfunction is a consistent feature of HD pathology (Bennett et al., 2007). 
While UPS mainly degrades short nuclear and cytosolic proteins, bulk degradation of 
cytoplasmic proteins or organelles is largely mediated by macroautophagy (also known as 
autophagy) (for review Chu, 2006). Increased autophagy was previously found in HD, probably as a 
response to reduce the toxicity induced by the aggregates (Sapp et al., 1997). 
 
II. Caspase activation  
Proteases (including caspases, calpains and aspartyl endopeptidades) are involved in cleavage 
of Htt within the N-terminal domain (Graham et al., 2006). Several studies demonstrated that Htt is a 
caspase substrate with defined sites for caspase-3 at amino acids 513 and 552, for caspase-2 at amino 
acid 552, and for caspase-6 at amino acid 586 (Wellington et al., 1998, 2000). Two caspase-3 
consensus sites at amino acids 530 and 589 that appear to be silent have been also decribed (Graham 
et al., 2006). Htt is cleaved by caspase 3 and 6 in vitro, and caspase-3-cleaved Htt fragments have 
been identified in HD brain, prior to the clinical onset. This suggests that N-terminal Htt fragments 
may play a role in HD pathogenesis (Graham et al., 2006). Both wild-type and mHtt can be cleaved 
by proteases, but fragments generated from wild-type Htt appear to be more efficiently cleared 
through the ubiquitin–proteasome pathway (Wellington et al., 2002). Such fragments were mainly 
detected in cytoplasm, which may indicate that this precedes nuclear uptake of N-terminal Htt 
fragments (Wellington et al., 2002). 
MHtt can also reduce the ability of Htt to bind and inhibit active caspase-3 and to bind HIP1 
(Htt interaction –protein 1), which is then free to associate with HIPP1 (HIP1-protein interactor) and 
activate caspase-8, an initiator caspase involved in the apoptotic cascade (for review, Gil and Rego, 
2008, a review). In FVB-YAC128 mice expressing full-length mHtt, the inhibiting of caspase-6 (but 
not caspase-3) was shown to protect loss against striatal volume and neuronal loss, suggesting that 
caspase-6-mediated proteolysis of mHtt (586 aa), generating a toxic fragment and mediates 
excitotoxic stress. Cleavage of Htt could be an ‗initiating‘ factor for neuronal dysfunction, by 
generating toxic fragments, altering cellular trafficking and gene expression patterns and activating 
cell death pathways via altered interaction with Htt-associated proteins (Figure. 1.10.) (Wellington et 
al., 2003). Htt proteolysis could also act as a feed-forward loop, in which cleavage may occur prior 
to the onset of neurodegeneration in HD, and initiate or exacerbate progression towards activation of 
cell death proteases and subsequent cell death (Wellington et al., 2003). 
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Calpains are a family of Ca
2+
-dependent intracellular cysteine proteases, activated by elevated 
intracellular calcium levels, which cleave Htt between amino acids 437 and 540 an area that overlaps 
with caspase cleavage sites in the protein (amino acids 518–586) (Wellington et al., 2003). 
 
III. Transcription deregulation  
It has been proposed that mHtt interacts with several transcriptional factors recruiting them 
into the aggregates and inhibiting their activity (for review, Bithell et al., 2009). Important 
transcriptional factors (e.g. CREB [cyclic-adenosine monophosphate (cAMP) response element 
(CRE)] binding protein (CBP) (Steffan et al., 2000; Nucifora et al., 2001), specific protein-1 (SP1) 
(Li et al., 2002), TATA-binding protein (TBP), TBP-associated factor TAFII130 (Dunah et al., 
2002) and the pro-apoptotic transcription factor p53) directly interact with mHtt (Steffan et al., 
2000). CBP, with a polyQ stretch, is sequestrated into mHtt aggregates, suppressing CREB-mediated 
CRE transcription (Steffan et al., 2000). TBP, also containing a polyQ stretch, and was shown in an 
in vivo study to be incorporated into mHtt aggregates and to suppress its DNA binding by mHtt 
(Steffan et al., 2000). SP1, which binds to glutamine-rich region in certain promoters and activates 
Fig. 1.10. The toxic fragment hypothesis. Cleavage of Htt generates toxic N-terminal fragments 
that, when containing expanded polyQ tracts, are not efficiently degraded and accumulate within 
cells. Resulting fragments initiate several changes in the cell. (Adapted from Wellington et al., 
2003). 
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transcription of the corresponding genes and TAFII130 interacts with a soluble form of mHtt, 
suppressing of SP1 transcriptional activity and finally downregulating dopamine D2 or nerve growth 
factor receptor (Steffan et al., 2000). p53 is incorporated into mHtt aggregates via its SH3 sequences, 
leading to repression of p53-mediated transcription (Steffan et al., 2000).  
Interaction of mHtt fragments with transcriptional factors is sufficient for transcriptional 
deregulation in vivo suggesting a model whereby mHtt interacts directly with DNA, altering its 
conformation and transcription factor binding and ultimately leading to transcriptional deregulation 
(Benn et al., 2008). Benn et al. (2008) observed that both wild-type and mHtt occupy gene promoters 
in vivo and proposed the enhanced genomic DNA binding by mHtt, (facilitated by its nuclear-
localization) alters DNA conformation and subsequent binding of transcription factors, disrupting 
normal control of mRNA expression at an early time point in HD pathogenesis. Several transcription 
factors that interact with the mutant protein have acetyltransferase activity that may impair gene 
expression, by altering histone acetylation levels. Hypoacetylation has been linked to repression of 
gene activity (Sadri-Vakili et al., 2006) 
mHtt can also inhibit gene expression in the cytosol (Zuccato et al., 2003). Wild-type Htt was 
found to interact with the repressor element-1 transcription factor (REST) in cytoplasm. REST 
associates with neuron restrictive silencer factor (NRSF) to affect nuclear transcription of neuronal 
genes, including that of BDNF. This interaction REST– NRSF could prevent their entry to nucleus 
and thus reduce their suppression of gene expression. However mHtt bind weakly with REST–
NRSE, leading to increased accumulation of REST–NRSF in nucleus and subsequent inhibition of 
BDNF and other genes expression (Zuccato et al., 2003). 
 
IV. Disruption of axonal transport 
Several Htt-binding cytoplasmic proteins are involved in vesicle trafficking and intracellular 
transport. A particular protein, HAP 1, was proposed to facilitate the interaction with microtubule 
motor proteins, forming a complex with kinesin (plus-end directed microtubule motor protein) and 
with p150
Glued
 subunit of dynactin (Caviston et al., 2007). A study demonstrated a co-precipitation of 
a complex that includes cytoplasmic dynein, dynactin, Htt, kinesin and HAP1 (Caviston et al., 2007). 
HAP1 is a multidomain protein with versatile functions that also interacts with HGS, which in turn 
participates in endocytosis of the epidermal growth factor (EGF) receptor (Gauthier et al., 2004). 
HAP1 was recently found to interact with the type 1 inositol (1,4,5)-trisphosphate receptor (IP31), 
forming an IP31–HAP1A–Htt ternary complex in which the mHtt enhances the sensitivity of IP31 to 
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inositol (1,4,5)-trisphosphate (for review, Li and Li., 2004). HAP1 interacts with NeuroD (a 
transcription factor important for neuronal development and survival) and Htt interacts with NeuroD 
via HAP1 (for review, Gil and Rego, 2008). Htt has also been linked to actin-based motors through 
optineurin, a protein that links myosin VI to Golgi membranes (Caviston et al., 2007). A 
neurotrophic factor essential for neuronal survival, BDNF, is decreased in striatal neurons. BDNF is 
secreted by cortical neurons, delivered by axonal transport and re-endocyted by striatal neurons 
(Gauthier et al., 2004). In several studies, it was shown that mHtt plays an important role such 
depletion, as a consequence of defective axonal trafficking (Gauthier et al., 2004). A study 
demonstrated an increased association of polyQ-Htt to HAP1 and p150
Glued
, leading to the depletion 
of HAP1, p150
Glued
, dynein IC (intermediate chain), and kinesin HC from microtubules (Gauthier et 
al., 2004). This occurs mainly in the early stage of disease, while in later stages neuritic aggregates 
accumulate and contribute to reduce axonal transport (Gauthier et al., 2004) 
 
V. Synaptic dysfunction 
Interactions of mHtt with cytoplasmic proteins have been involved in synaptic dysfunction, 
either by impairment of axonal transport or sequestration of synaptic vesicles or proteins necessary 
for endocytosis and recycling (e.g. membrane receptors) (Trushina et al., 2006). Inhibition of 
endocytosis occurs through a non-clathrin, caveolar related pathway (Trushina et al., 2006). A recent 
study revealed that mHtt leads to accumulation of intracellular cholesterol, which is essential to 
promote synapse formation and maintenance membrane integrity in CNS (central nervous system) 
neurons (Trushina et al., 2006). 
Another Htt-interacting protein is the neurospecific phosphoprotein PACSIN 1/syndapin, 
which is located along neurites and within synaptic boutons and has been implicated in synaptic 
vesicle recycling (Modregger et al., 2002). Interaction through C-terminal SH3 domain with mHtt 
leads to re-localization of PACSIN 1 away from varicosities towards neuronal cell body (Modregger 
et al., 2002). SH3-containing proteins, binding partners for synaptojanin and dynamin I, play a major 
role in signal transduction from membrane receptors and in regulation of exo/endocytic cycle of 
synaptic vesicles (Sittler et al., 1998). MHtt was also found to bind to this domain and may 
contribute to neuronal cell death (Sittler et al., 1998). Another example of loss of function is HIP14 
(a neuronal protein that is located mainly in Golgi apparatus and cytoplasmic vesicles) that interacts 
strongly with wild-type Htt but weakly with the mutant protein and may compromise intracellular 
traffic (Singaraja et al, 2002) 
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Several proteins involved in exocytosis are decreased in HD, including complexin II (Smith 
et al., 2005). Complexin II interacts with the soluble N-ethylmaleimide-sensitive fusion protein 
attachment protein receptor (SNARE) complex (involved in neurotransmitter release and regulation 
of membrane fusion between the synaptic vesicle and the presynaptic plasma membrane) (Smith et 
al., 2005). Another protein whose levels are decrease is rabphilin 3A that is involved in priming and 
docking of vesicles to the plasma membrane (Smith et al., 2005). 
Excitotoxicity induced by glutamate has been implicated as one of the main causes of 
neuropathology of HD (Fan and Raymond, 2007). R6 transgenic mice have an increased release and 
a decreased clearance of glutamate by the glial cell glutamate transporter GLT1 with subsequent 
sustained glutamate stimulation of striatal neurons (Smith et al., 2005). Neurons from mice R6/2 
were shown to have increased responses of NMDA and decreased Mg
2+
 sensitivity, suggesting that 
NMDA receptor alterations may occur very early in development and that constitutively abnormal 
NMDA receptors with enhanced response may be present (Starling et al., 2005). MHtt facilitates 
activity of NR2B subtype of NMDARs and InsP3R1, causing influx of Ca
2+
 (Tang et al., 2004). 
Activation of glutamatergic receptors alters Ca
2+
 homeostasis, which in turn affects downstream 
pathways and initiate second messenger cascades (Fan and Raymond, 2007). When buffering 
capacity is compromised, activation of catabolic enzymes (such as nucleases, proteases and 
phospholipases) as well as generation of free radicals and induction of mitochondrial damage can 
occur (Fan and Raymond, 2007).  
Metabotropic glutamate receptors (mGluR) (e.g. mGluR1, mGluR2 and mGluR3) and 
ionotropic receptors (3-hydroxy-5-methyl-4-propionate (AMPA) and kainate receptors (KA)) as well 
as D1 and D2 dopamine (DA)  receptors were also found to be decreased or with decreased binding 
activity in R6 ⁄ 2 mouse model (for review, Gil and Rego, 2008). 
Interestingly, normal Htt associates with postsynaptic density 95 (PSD-95), a scaffold protein 
that causes clustering and activation of receptors in postsynaptic membrane. Decreased interaction of 
mHtt with PSD-95 may activate NMDARs (Li and Li, 2004). 
 
VI. Mitochondrial dysfunction 
Defects in mitochondrial respiratory chain in caudate/putamen of HD patients have been 
reported include severe reduction in activity of complex II/III and milder decrease of complex IV 
activity (Sawa et al., 1999). Transcriptional impairments produced by mHtt could lead to disruption 
of Ca
2+
 homeostasis, which may further reduce CREB-dependent expression of mitochondrial 
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oxidative phosphorylation proteins (Gopalakrishnan and Scarpulla, 1999). Mitochondrial respiration 
and ATP production were found to be significantly impaired in striatal cells expressing mHtt. 
Moreover, mHtt can also affect mitochondrial function by inhibiting expression of PGC-1α 
(peroxisome proliferator-activated receptor gamma co-activator 1-alpha), a transcriptional factor 
required for expression of numerous genes that promote the detoxification of reactive oxygen species 
(ROS) and prevent oxidative stress (Quintanilla and Johnson, 2009, for review). Tang et al. (2004) 
propose that such vulnerability could arise from glutamate released by corticostriatal projection 
neurons, stimulating NR1/NR2B-composed NMDARs and mGluR5 receptors. Activation of 
NR1/NR2B NMDARs leads to Ca
2+
 influx and activation of mGluR5 receptors through the 
production of InsP3 and Ca
2+
 release via InsP3R1. Indeed, mHtt sensitizes InsP3R1 to activation by 
InsP3, stimulating NR1/NR2B NMDAR activity, and directly destabilizing mitochondrial Ca
2+
 
handling. As a result, an abnormal Ca
2+
 response in MSN occurs, leading to an overload in cytosolic 
Ca
2+
, which is then taken into mitochondria via Ca
2+
 uniporter/channel. If this occurs continuously, 
changes storage capacity limit of mitochondrial Ca
2+
 can lead to opening of mPTP (mitochondrial 
permeability transition pore), release of cytochrome c into cytosol, and activation of caspase-
mediated intrinsic apoptotic program (Oliveira et al., 2007). MHtt can also interact directly with 
outer mitochondrial membrane increasing the sensitivity of the mPTP to Ca
2+
 or other apoptotic 
stimuli and also the aggregates could impair mitochondrial movements along neuronal processes (for 
review, Damiano et al., 2010) 
Weydt et al. (2006) found a decreased number of functional mitochondria, ATP/ADP and 
expression of PGC-1α target genes (involved in energy production) in brown adipose tissue from HD 
mice (N171-82Q mice). This suggests that inhibition of PGC-1α (usually involved in adaptive 
thermogenesis) may cause a global defect in mitochondrial function in HD mice. The authors also 
showed that these HD mice develop hypothermia associated with impaired activation of brown 
adipose tissue-mediated thermogenesis, supporting the hypothesis that impaired PGC-1α activity 
links neurodegeneration-associated mitochondrial dysfunction to thermoregulatory and metabolic 
defects in HD (Weydt et al., 2006). 
Normal average rectal temperature in mice is 37.5
o
C, but it depends on circadian fluctuations 
and is highly decreased during fasting (especially at noon) (Swoap in Howard Hughes Medical Institute, 
2010) (Figure 1.11.). 
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Fig.1.11. Daily body temperature fluctuations in a mouse under fed and torpor conditions. 
[Obtained from Http://www.hhmi.org/news/popups/images/20060131_graph.jpg, Steven J. Swoap, Howard 
Hughes Medical Institute] 
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1.2. Metabolic changes in HD 
1.2.1. Glucose metabolism 
 Under normal conditions glucose is the main substrate for cerebral energy metabolism. But in 
particular circumstances, the brain also consumes monocarboxylic acids, including lactate and 
ketone bodies, acetoacetate and β-hydroxybutyrate (Owen et al., 1967). In glycolysis, glucose is 
degraded to pyruvate and then to lactate (Figure 1.12.). This process is not very energy-efficient, 
resulting only in the production of 2 mol of ATP/mol of glucose and in regeneration of reducing 
equivalents (the oxidized form of nicotinamide-adenine dinucleotide, NAD
+
). Then, pyruvate can 
enter the tricarboxylic acid cycle (or Krebs cycle) and produce 34 mol of ATP/mol of glucose via 
mitochondrial oxidative phosphorylation having a potential to generate a total of 38 mol of ATP/mol 
of glucose (Guyton and Hall, 1998). 
 
 
Fig. 1.12. Glycolytic pathway leading to phospholipid formation, lactate and pyruvate a substrate to the 
citric acid cycle. F-1,6-DP, fructose-1,6-diposphate; DHAP, dihydroxyacetone-phosphate; GA-3P, 
glyceraldehyde-3-phosphate; G-3-P, glycerol-3-phosphate; FFA, free fatty acids; La/py, lactate/pyruvate; a-
KG, α-ketoglutarate. (Adapted from Nordström, 2008) 
 
 
In a recent study, glucose metabolism was found to be significantly decreased in striatum and 
temporal and frontal cortical lobes, in both preclinical and affected HD patients, with marked striatal 
hypometabolism is seen in later stages of disease reflecting neuronal atrophy (Ma et al., 2007). 
Thalamic hypermetabolism and cortical hypometabolism and hypoperfusion have also been detected 
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in early stage of symptomatic HD patients with Positrons Emission Tomography or Single Photon 
Emission Computed Tomography (Ma et al., 2007). 
As it was described previously mHtt and its fragments can interfere with energy production, 
through interaction with a variety of key proteins involved in energy metabolism. MHtt has been 
found to interact with a important enzyme involved in glycolysis GAPDH (glyceraldehyde-3-
phosphate dehydrogenase), partially inhibiting its activity in a disease progression dependent manner 
and as more fragments interact with GAPDH, causing a significant decrease in ATP production 
culminating in cell death (Wu et al., 2007). 
MHtt is also known to interfere with oxidative phosphorylation, the final step in ATP 
production pathway. Defects in HD respiratory chain have been observed, since mHtt can 
dramatically decrease the activity of complex II/III and mildly complex IV. This could be probably 
due a preferential decrease of respiratory chain enzymes, in particular complex II (SDH/II - succinate 
dehydrogenase) and to a lesser extend cytochrome c oxido-reductase (IV) (for review, Damiano et 
al., 2010). 
It has been widely described that HD patients have increased brain lactate levels, suggesting 
that damage to mitochondria and impaired energy metabolism may occur in the disease, leading to 
conversion of pyruvate in lactate to generate ATP (Koroshetz et al., 1997). Although glucose is the 
primary energy source for neurons and astrocytes, the first can utilize glial-produced lactate as an 
additional energy substrate under abnormal conditions (Pellerin L and Magistretti, 1994). Increased 
lactate reflects metabolic and energy impairment, resulting in tissue acidosis which in turn induce 
glial and neuronal cell swelling (Koroshetz et al., 1997). It has been described that pyruvate 
concentrations are significantly lower in HD patients group, which may also increase the L/P ratio 
(Koroshetz et al., 1997) 
A condition unexpected and often found in HD patients is weight loss and muscle wasting 
(Gaba et al., 2005). The disease is often accompanied by considerable weight loss, particularly on its 
final stages, which seems directly associated with the number of CAG repeats (Aziz et al., 2008). 
Patients with higher body mass index were linked with slower progression of HD (Myers et al., 
1991). HD patients are either underweight (Djoussé et al., 2002), or tend to lose weight during the 
course of their illness, eventually becoming cachectic in end-stage (Aziz et al., 2008). Although the 
reason for weight loss remains debatable, it seems to be unrelated to anorexia-mediated decrease 
food intake, since these patients normally have increase caloric uptake (Trejo et al., 2004). Some 
studies referred increased motor activity could be involved in weight loss (Pratley et al., 2000), 
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whilst others referred a hypermetabolic state, leading to a negative energy balance (Aziz et al., 2008; 
Goodman et al., 2008). One study reported that total energy expenditure was 11% higher in HD 
patients (Gaba et al., 2005). The majority of presymptomatic HD patients also present an altered 
metabolic profile which may therefore represent an early step in HD pathogenesis and general 
metabolic derangement (Gaba et al., 2005). 
 
1.2.2. Diabetes mellitus in HD 
When glucose metabolism is impaired and glucose uptake by cells is reduced, blood glucose 
levels rise. If this occur chronically a metabolic disease, Diabetes Mellitus, can arise (WHO, 2006). 
The most common Diabetes mellitus forms are type I and type II. Type I diabetes is characterized by 
loss of insulin-producing β-cells in pancreatic islets of Langerhans leading to insulin deficiency. In 
type II diabetes insulin resistance is the main characteristic and, initially, there is no reduction in 
insulin secretion, but a deficient response to insulin (James and Piper, 1994).  
In HD there is some controversy on the prevalence of diabetes. The first paper describing a 
higher prevalence of diabetes in HD was Podolsky et al. (1972) in which 50% of the patients studied 
had impaired carbohydrate metabolism, probably due to decreased insulin secretion. In 1985, Ferrer 
studied 620 probands with HD and found that 65 of them (10.5%) had diabetes, suggesting that HD 
patients had 7 times more probability of have diabetes. A more recent study, focused on changes in 
insulin sensitivity and insulin resistance, major determinants of glucose homeostasis, in a group of 
consecutive normoglycemic patients with HD, showed impairment in insulin secretion capacity, 
accompanied by simultaneous decrease in insulin sensitivity and an increase in the insulin resistance 
(Lalić et al., 2008). A possible explanation may involve mHtt inclusions (expressed also in 
pancreatic β-cells) that become dysfunctional and leads to diabetes 2 (Andreassen et al., 2002). 
However, this relation was not found in another study, perhaps because the patients studied had 
different anthropometric features (Boesgaard et al., 2009). Moreover, mice models were also shown 
to develop glucose intolerance and glycosuria (R6/2 (Bjőrkqvist et al., 2005); R6/1 transgenic mouse 
(Josefsen et al., 2008) and HD-N171-82Q mice (Schilling et al., 1999)). Recently, Hunt et al. (2005) 
found that 70 % of R6/2 mouse at 14 weeks of age develop diabetes and its severity was associated 
with progressive formation of ubiquitinated inclusions in pancreatic β-cells. Accumulation of such 
aggregates was associated with selective disruption in expression of transcription factors essential for 
glucose-responsive insulin gene expression leading to in impairment of insulin release rather than 
insulin resistance (Hunt et al., 2005). Bjőrkqvist et al. (2005) identified two separate pathological 
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processes that may be responsible for diabetes in R6/2 mice: impaired β-cell replication (resulting in 
deficient β-cell mass (~35%) most likely due to impaired regeneration of islet cells) and a reduction 
of insulin-containing secretory granules (abrogating stimulated hormone secretion). R6/1 mice, 
carrier of a shorter CAG repeat, although not diabetic, shows impaired glucose tolerance (Josefsen et 
al., 2008).  
 
1.3. In vivo models of HD 
The most reliable models reproduce neuropathological hallmarks such as degeneration of 
GABAergic medium spiny neurons at an early stage and cortical loss in advanced conditions and 
especially the phenotype of the disease (for review, Rubinsztein, 2002). Two categories of animal 
models were generated: the non-genetic and the genetic ones. Non genetics animal models were the 
only available before discovery of gene mutation and used excitotoxic mechanisms or mitochondrial 
dysfunction to induce neurodegeneration, primarily at striatum. Quinolinic acid (QA) and kainic acid 
(KA) are the most commonly used excitotoxic agents, acting as agonists of NMDA receptors, 
whereas 3-nitropropionic acid (3-NP) and malonic acid (MA) induce cell death in striatal neurons 
through inhibition of mitochondrial complex II (succinate dehydrogenase), disrupting mitochondrial 
electron transport chain with subsequent impairment in ATP synthesis (for review, Ferrante, 2009).  
Recently, genetic engineering led to the production of transgenic animals, inserting genetic 
material in the host genome or into the Htt gene locus, resulting in knock–in models. In HD cases, 
the material inserted comprised protein-coding region exon -1 (which expresses truncated protein) or 
the full length Htt gene, expressing the entire protein (for review, Ferrante, 2009). The most widely 
used animals are rodents and, recently, also non-human primates (Yang et al., 2008), but other non-
mammalian animals exist (such as Caenorhabditis elegans, Drosophila melanogaster and Zebrafish) 
(Fecke et al., 2009). These models are simple and have a rapid development, allowing high-
throughoutput testing of novel therapeutic compounds and strategies (Fecke et al., 2009).  
Currently, a wide range of models is available, differing in background, fragment/full-length 
gene, CAG repeat length, promoter and endogenous expression of transgene. Those particular 
characteristics of each model influence the disease neuropathology and phenotype (for review, 
Ferrante, 2009). Frequently there is an inverse correlation between the severity of disease/symptoms, 
lifespan and mHtt expression and transgenes length (for review, Ferrante, 2009). The full-length 
models are genetically more accurate, but the fragment models have a rapidly disease progression 
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with a robust phenotype, well-defined behavioural and neuropathological findings and premature 
death between 13 and 18 weeks of age (e.g. Carter et al., 2000).  
For the purpose of this work, in the next sub-section we will focus on the transgenic models 
expressing full-length mHtt. 
 
1.3.1. Full-length human HD gene transgenic mouse models 
In 1999 Hayden and colleagues developed a YAC (yeast artificial chromosome) transgenic 
mouse using a YAC vector system to express the entire human Htt gene under control of the human 
Htt promoter. YAC mouse strains contain either 72 or 128 CAG repeats. The mice with 72 
expansions show a selective degeneration of medium spiny neurons in the lateral striatum with the 
translocation of N-terminal Htt generation specifically in the striatum (Hodgson et al., 1999). The 
YAC128 has an increased size of CAG expansion of 128 CAG and in 2003 Slow et al. characterize 
the natural history of disease in these mice. Motor abnormalities and age-dependent brain atrophy 
were found. In early stages of disease the mice develops a hyperkinetic phenotype manifest at 3 
months of age, followed by a progressive motor deficit on the rotarod at 6 months with progression 
to hypokinesis by 12 months of age. There is a high correlation between motor abnormalities and 
striatal atrophy, which is evidently at 9 months of age, and develops into cortical atrophy at 12 
months and significant decrease (~15%) in striatal neurons accompanied by a decrease in striatal cell 
surface area.  
The motor deficit at 6 months correlates well with evident neuronal loss at 12 months, 
suggesting that early motor dysfunction might be an indicator of the severity of the extent of 
dysfunction of striatal neurons YAC128 mice also develop mild cognitive deficits, which precedes 
the onset of motor abnormalities and progressively deteriorate with age (Van Raamsdonk et al., 
2007). Htt inclusions appear latter to behavioral and neuropathological changes associated with 
neuronal death, at 18-month-old, presupposing that inclusions are not the main cause to neurons loss. 
Excitotoxicity was described has the most important mechanism responsible for cell death in which 
disturbed neuronal Ca
2+
 signaling is involved. An increased NMDAR-mediated current in the MSN 
cultured from the YAC128 model corroborates this idea (Shehadeh et al., 2006, Van Raamsdonk et 
al., 2007; Zhang et al., 2008). This susceptibility to neuronal excitability is age-dependent in 
YAC128 which may be conditioned by background strain since FVB/N WT mice have an age-
dependent decrease in susceptibility to excitotoxic stress probably resulting from morphological 
changes including decreases in synaptic density, spine density and loss of distal dendritic segments 
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(Graham et al., 2009). Body weight in YAC128 mouse line is increased at 2 month of age (Van 
Raamsdonk et al., 2007) represented by an increase in both fat mass and fat-free mass influenced by 
Htt which modulates the IGF-1 pathway (Pouladi et al., 2010). 
 
 
[Adapted from Van Raamsdonk et al., 2007] 
 
YAC128 mice were initially generated on the FVB/N background strain based on its 
advantages in generating transgenic mice and its known susceptibility to excitotoxicity (Taketo et al., 
1991). This strain has a particular characteristic that makes it attractive to create HD transgenic mice, 
since it exhibits a high degree of neuronal loss when exposed to excitotoxic stress after injection of 
kainic acid or quinolinic acid, in an age dependent manner, not experienced in other HD transgenic 
strains (Schauwecker et al., 2002, Graham et al., 2009). YAC128 are useful to assess therapeutical 
interventions, since it reproduces well the phenotype of disease in humans. 
 
 
Table IV- Comparison of the YAC72 and YAC128 mouse models of Huntington disease.  
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1.4. Hypothesis and aim of this thesis 
As described above, HD is a multifactorial neurodegenerative disease, characterized by 
cognitive deficit, motor abnormalities, weight loss, endocrine changes (Foroud et al., 1999). The 
later may include impaired carbohydrate metabolism, diabetes and changes in insulin sensitivity and 
insulin resistance, which are major determinants of glucose homeostasis (Podolsky et al., 1997, Lalić 
et al., 2008). Although such evidences remain controversial in human HD patients, they have been 
well characterized in the R6/2 mouse model (Bjőrkqvist et al., 2005), expressing the exon-1 of 
human mHtt. However, to our knowledge, no studies have been performed in HD animal models 
expressing full-length mHtt. 
The YAC128 mouse expresses full-length mHtt with 128 glutamines and present a phenotype 
and history course similar to HD patients, namely the motor impairment, cognitive decline, striatal 
neuronal loss and metabolic dysregulation (Slow et al., 2003, Van Raamsdonk et al., 2007). 
However, and in contrast to HD patients, these mice show increased body weight (Slow et al., 2003, 
Van Raamsdonk et al., 2007; Pouladi et al., 2010). Furthermore, the YAC128 transgenic mice have 
been created in a background strain susceptible to metabolic deregulation and insulin resistance, the 
FVB strain (e.g. Junghyo et al., 2009). Under this perspective, we hypothesized that expression of 
full-length mHtt in an hyperglycemic background (conferred by the FVB strain) could aggravate 
motor impairment, changes in body weight and metabolic deregulation and possibly insulin 
resistance. 
Therefore, the aim of the present study was to evaluate the effect of hyperglycemic 
background on peripheral and central metabolic parameters in an in vivo rodent model of HD 
expressing full-length mHtt. In this regard, we used hyperglycemic 6 month-old YAC128 mice 
versus age-matched WT (FVB/N) mice littermates. 
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2.1. Materials 
Avertin (Tribromoethanol) syringes 1ml Plastipak® from BD (Franklin Lakes, USA). 
Needles 1,1x40 mm, paraformaldehyde 4% (0.1 M PBS at pH 7.4), Sodium Azide, Eppendorf from 
Bioplastics BV, Netherlands, Centrifuge 5417C (Eppendorff
®
). Digital glucometer, The OneTouch® 
Ultra®, and compatible stripes were from Johnson & Johnson Company (Milpitas, CA, USA). High-
precision electronic weighing scale Kern 440-47 N® was from Kern & Sohn GmbH (Balingen, 
Germany) and the digital thermometer, Ved digital II® from Artsana S.P.A. (Grandate, Italy). 
Rotarod and Open Field apparatus were from Panlab® (Barcelona, Spain). PCR reagents, such as 
MasterMix, Buffer, MgCl2, and Taq Polymerase, and also proteinase K, DNA Ladder 100 bp and 
DNA Loading Dye were purchased to Invitrogen® (Carlsbad, CA, USA). D-Glucose and human 
recombinant insulin was from Sigma-Aldrich Co (St. Luis, MO, USA) were reconstituted in MiliQ 
water. Insulin (Mouse) Elisa kit was obtained from ALPCO (Salem, USA). Quantikine® Mouse/Rat 
IGF-I Immunoassay was purchased to R&D Systems, Inc. (Minneapolis, USA). Pyruvate Assay Kit 
(ab65342) and Lactate Assay Kit (ab65331) were both obtained from Abcam (Cambridge, UK). 
Methylene Blue (1%). HPLC column Lichrospher 100 RP -18 (5 µm) was from Merck (Darmstadt, 
Germany). All other reagents were of the highest purity grade commercially available. 
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2.2. Animals 
All procedures were performed in 6 month old male mice. Two groups were compared, wild-
type mice from FVB/N strain (n=13, representing the control) and YAC128 transgenic mice with 
FVB/N background (n=12), both obtained from our local colony with breeding couples gently 
provided by Michael Hayden (University of British Columbia, Vancouver, Canada). 
All animal studies were performed according to the Helsinki Declaration and EU guidelines 
(86/609/EEC). All mice were reared in cages, housed at CNC animal facilities, in controlled 
temperature and humidity room and maintained at 12 h light/dark cycle, with ad libitum access to 
water and food. At the end of the study, mice were sacrificed after anesthesia with Avertin
®
 to 
collect tissues and blood, Blood was collected by intracardiacal punction with a heparinized syringe, 
and centrifuged at 5 000 xg, for 2 min, at 4º C, in an Eppendorf Centrifuge 5415C. The hematocrit-
containing pellet was removed and serum was sampled into sterile eppendorf tubes and frozen at -
20ºC to posterior analysis. Mice were perfused with PBS (1%) at PH 7.4 (0.2 M sodium phosphate 
dibasic, 0.2 M potassium phosphate monobasic) to eliminate blood clots from tissues and the brain 
was removed and dissected. One hemibrain was fixed in 4% paraformaldehyde, prepared in 0.1M 
PBS, pH 7.4. After the brain was settled, the solution was replaced by 20% glucose in PBS (1x), 
containing (~1%) sodium azide (a bacteriostatic compound that prevents bacterial contamination).  
The other hemibrain was snap frozen at -80ºC for posterior analysis. Then, the hemibrain was 
unfrozen and homogenized in 2 ml PBS with a Potter-Elvejhem homogenizer with a Teflon pestle, at 
300 rpm  to obtain an homogenized, and kept at -20ºC. 
 
2.2.1. Assessment of body weight and temperature 
Body weight and temperature was assessed in early afternoon, before behaviour tests or 
glucose and insulin tolerance tests (GTT and ITT, respectively). Rectal temperature was monitored 
with a digital thermistor thermometer (Artsana
®
). 
 
2.3. Genotyping 
Three weeks old mice were genotyped by using a tail-tip DNA Polymerase Chain Reaction 
(PCR) procedure. PCR is a highly sensitive and specific technique for the amplification of nucleic 
acid (Kary Mullis, 1983). DNA was extracted from a portion of dissected mouse tail placed in an 
eppendorf tube containing proteinase K, by adding 700 µl of Lysis Buffer, according to a previously 
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described procedure (Mangiarini et al., 1999). The site of cleavage for this enzyme is the peptide 
bond adjacent to the carboxyl group of aliphatic and aromatic amino acids with blocked alpha amino 
groups (Manak, 1993). The main task consisted in protein digestion and removal of contaminants 
from preparations of nucleic acids, since they rapidly inactivate nucleases that may otherwise 
degrade DNA or RNA during purification (Manak, 1993). Preparations were incubated overnight at 
56ºC. After this procedure, supernatant was removed and 200 µl of overconcentrated NaCl were 
added to each eppendorf tube. After a 2 min centrifugation at 14000 rpm, the pellet was removed and 
500 µl of iced pure alcohol was added, forming a ―cloud‖ of DNA. This ―cloud‖ was removed and 
700 µl of 70% alcohol was added to rehydrate. The supernatant was removed and the DNA attached 
to eppendorf tube was left to dry. DNA was resuspended with 200 µl of TE (Tris EDTA) and the 
optical density was spectrophotometrically measured at 260 nm and 280 nm, being the difference the 
value of interest which corresponds to the difference between the reference and a sample. 
To perform PCR, Master Mix (containing buffer (5x), MgCl2 (25 mM), dNTP (10 mM), 
primers and Taq polymerase) and milliQ water were added to the DNA sample, in a final volume of 
25 µl, according to the procedure described by The Jackson Laboratories protocol. The primers were 
(Invitrogen®): 
 
LyA1 – CCT GCT CGC TTC GCT ACT TGG AGC  
LyA2 – GTC TTG CGC CTT AAA CCA ACT TGG 
RyA1 – CTT GAG ATC GGG CGT TCG ACT CGC 
RyA2 – CCG CAC CTG TGG CGC CGG TGA TGC 
Actin Foward – GGA GAC GGG GTC ACC CAC AC 
Actin Reverse – AGC CTC AGG GCA TCG GAA CC. 
 
The PCR protocol consisted of 35 cycles with the following temperatures and times for each 
steps: denaturation – 94ºC for 30 s; annealing – 63ºC for 30 s; elongation – 72ºC for 30 s. At the end 
of the cycles, DNA was left at 70ºC for 10 min.   
A 1,7% agarosis gel was made and the samples were mixed with DNA Loading Dye and 
pippetted onto the wells. Template was a DNA ladder with 100 bp. An agarosis gel electrophoresis 
was performed at a constant voltage of 120 mV. Gel imaging was acquired in a VersaDoc Imaging 
System® (BioRad, Hercules, USA), using BioRad Quantity One software. 
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2.4. Behaviour analysis 
 To measure motor ability, exploratory capacity and anxiety in mice, two behavioural test 
paradigms were performed: the rotarod and the open-field tests. Animals were brought in their cages 
to the test room at least 1 hr prior to the start of behavioural testing, where they remained until the 
beginning of the test. Procedures were consistent for all subjects, with tests made in lit room, 
temperature of 25
o
C and minimum noise levels. 
Behavioural equipment was cleaned thoroughly with 70% ethanol before and after each test 
session. After each animal completed its session, the equipment was also cleaned with 30% ethanol. 
In openfield test, the fecal boli and urine were removed and surfaces wiped out carefully, allowing 
the chamber to dry completely before another animal started the test. The experimenter wore a green 
lab coat during all the procedure. 
 
2.4.1. Rotarod Test 
The rotarod was designed to assess motor coordination, balance and equilibrium (Jones et al, 
1968). The equipment (PanLab
®
) available in our laboratory allows the simultaneous assessment of 5 
mice; however it was not the case in this study since we performed the tests individually. The rotarod 
unit has a base of Perspex with dimensions of 362 (wide) x 240 (diameter) x 400 (high) mm, an 
integrated drum (250 mm diameter) composed by a rod (30 mm diameter) and 5 lines (50 mm wide). 
Mice were gently grabbed by the tail and placed on the roller lane of the rotarod. Before the test, 
A B 
 
C 
Fig. 2.1. PCR analysis of DNA extracted from 
mouse tail samples. Agarose gel analysis show 
distinct bands between 100-1000 bp after 
ethidium bromide staining (Fig. 2.1. A). Analysis 
of the PCR products on agarose gel allows a clear 
distinction between normal (Fig. 2. 1. B) and 
expanded alleles (Fig. 2.1. C). Lane A-Marker, 
Lane B – Wild-type mouse, Lane C – YAC128 
mouse. 
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performed as described by Carter et al., (2001), mice were trained for 40 s at a constant speed of 4 
rpm, to allow familiarization with the equipment. After a two hour, each mouse performed was tested 
for four sessions on the rod, with a gradual acceleration rate from 4-40 rpm during 5 min, each one 
separated by a 30 min resting period. When the animal fell off the rod, the time latency to fall and 
rotation speed were automatically recorded. Other mouse behavioural parameters (e.g. number of 
turns on the rod) were also registered. Results were expressed as latency to fall of rotarod (s). 
 
2.4.2. Open Field Exploration Test 
 This test allows the assessment of novel environment exploration, general locomotor activity 
and an initial screen for anxiety-related behaviour (Gould et al., 2009). A session with an extended 
length (30 min) also provides reliable information about habituation to the increasingly familiar 
chamber environment (Bailey and Crawley, 2009. The system is composed by 2 square frames with 
22 x 22 cm size, a frame support and a control unit. Chamber walls and floor are made of transparent 
Plexiglass. The open field arena is divided into a grid of equally sized areas by infrared photocell 
beams or lines drawn on the chamber floor, for visual scoring of activity by the experimenter. 
FRAMES (photo beam sensors) are equipped with 32 infrared photocells, 16 placed in axis X and 16 
placed in axis Y. The photocell works at a wavelength of 950 nm and its information is multiplexed 
at a rate of 40Hz. The system gives data about fast (5 cm/s) and slow (2 cm/s) movements, fast and 
slow stereotypies, number of fast and slow rearing and number of fast and slow nose-pokes in the 
hole-board test.  
Mice were tested for 30 min, as described by Gould et al. (2009) the room had lights on and a 
record was made with a digital camera. To start the test, the mouse was placed in the centre of the 
chamber. The experimenter left the testing rooms after this procedure, since sudden motion or noise 
could greatly affect exploratory activity. Mice were allowed to freely explore the chamber for 30 min 
and each line crossed or photocell beam break were scored as one unit of activity. Defecation and 
grooming activity were also scored. At the end of the test, the mouse returned to home cage. Results 
were expressed as mean±SEM. 
 
2.5. Measurement of blood glucose levels 
Blood was collected from the caudal vein and blood glucose levels were measured using a 
glucometer (The OneTouch® Ultra®,) with compatible stripes, based on the reaction of glucose 
oxidation to gluconolactone, catalyzed by glucose oxidase (Yoo and Lee, 2010). Under normal, 
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healthy conditions mouse glycemia after a 4 hour fasting is ~100 mg glucose/dl blood (between 60-
130 mg glucose/dl blood) (Wong et al., 1999). Immediately after a meal and before insulin has time 
to be released and remove glucose from blood into the cells, glycemia may increase, returning to 
~100 mg/dl afterwards (Wong et al., 1999). Results were expressed as mg glucose/dl blood. 
 
2.6. Glucose Tolerance Test 
Glucose tolerance test (GTT) analyses the rate of glucose clearance from blood (American 
Diabetes Association, 2009). Food was removed at about midnight and mice were kept fasted for 12 
h, being GTT test performed around midday. Basal glycemia was measured before D-glucose 
injection, corresponding to time 0. Then, an intraperitoneal injection of 2 mg D-glucose/g body 
weight was given and glycemia were determined after 15, 30, 60 and 120 min. The injection was 
given after mouse immobilization by the back of the neck and then turned, with abdomen facing the 
experimenter. The tail was pull tightly back to avoid leg movement. Syringe needle containing the 
appropriate amount of glucose was inserted into the peritoneal cavity about 1cm inside of the 
mouse‘s right thigh, at a shallow angle. At the end of the test, cages were supplied with wet food. 
Results were expressed as mg glucose/dl blood. 
 
2.7. Insulin Tolerance Test 
Insulin tolerance test (ITT) analyses the capacity of cell membrane glucose transporters 
(GLUT) to uptake glucose, as a response to an increase in plasma insulin (Bruning, 1997). 
Mice were kept fasted for two hours, from noon to 2 p.m., in their cages. Basal glycemia was 
measured before insulin injection, corresponding to time 0. Then, an intraperitoneal injection of 1µU 
human recombinant insulin/g body weight was given to mice and glycemia were determined at 15, 
30, 60 and 120 min. At the end of the test, cages were supplied with wet food. Results were 
expressed as mg glucose/dl blood and as areas under the curve (AUCs), which were calculated using 
trapezoidal integration (Zou, 2001). Trapezoidal rule is a numerical integration method used to 
approximate the integral or the area under a curve. The integration of [a, b] from a functional form is 
divided into n equal pieces, called a trapezoid -        
 
 
. Each subinterval is approximated by the 
integrand of a constant value. In the case of GTT and ITT the integration was with the follow 
function:       
   
 
         
Where: 
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A- Glucose levels time tn 
B- Glucose levels time tn-1 
C- tn 
D- tn-1 
 
 
2.8. Assessment of plasma and brain levels of Insulin  
 Plasma and brain insulin levels were measured with a two site enzyme immunoassay (ELISA 
- Enzyme Linked Immuno Sorbent Assay) from ALPCO. Briefly, this assay is based on the ability of 
an antibody to bind with high specificity to one molecule, called an antigen (Beatty et al., 1987). 
Importantly, this immunoassay produces a measurable signal in response to a specific binding (in 
this case by differences in light observation measured with a spectrophotometer). Herewith, a mouse 
monoclonal antibody specific for insulin is immobilized into a 96-well microplate as the solid phase. 
Standards, controls, and samples added to the appropriate wells with a horseradish peroxidase 
enzyme labelled monoclonal antibody (Conjugate) result in insulin molecules sandwiching between 
the solid phase and the Conjugate (ALPCO protocol).  
According to manufacturer‘s instructions, brain homogenates and serum samples (10 µl) 
obtained as previously described were pippeted into the respective wells. Standards and reconstituted 
control were also placed in wells. Then, 75 μl of Working Strength Conjugate were pipetted into the 
wells and shaken for 2 h at 700-900 rpm, on a horizontal microplate shaker at room temperature. 
After incubation, the wells were washed with Wash Buffer to remove unbound Conjugate. Then, 100 
μl of TMB Substrate were added to each well, and the microplate was incubated on a microplate 
shaker at room temperature for 15 min. During this incubation, a blue color results from TMB 
Substrate reacting with bound Conjugate in the wells. Reaction was stopped by adding 100 μl of 
Stop Solution and the colour changed from blue to yellow. Optical density was measured by 
microplate reader (SPECTRAmax PLUS
®
) at 450 nm, with a reference wavelength of 620 nm. The 
intensity of yellow color is directly proportional to the amount of insulin in sample. Results were 
expressed as mean ±SEM. 
 
2.9. Assessment of plasma and brain levels of IGF-1  
Brain and serum determination of insulin-like growth factor-I (IGF-I) levels was made using 
a Quantikine Mouse/Rat IGF-I Immunoassay from R&D Systems composed of a solid-phase ELISA 
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with E. coli-expressed recombinant mouse IGF-I and antibodies raised against the recombinant 
factor (Beatty et al., 1987). This assay employs the quantitative sandwich enzyme immunoassay 
technique, in which a monoclonal antibody specific for mouse/rat IGF-I has been pre-coated onto a 
microplate.  
According to manufacturer‘s instructions, blood sera were diluted 500 times with Calibrator 
Diluent RD5-38, by adding 10 µl sample to 490 µl of Calibrator Diluent RD5-38. The 500–fold 
dilution was completed adding 15 µl of this solution to 135 µl of Calibrator Diluent RD5-38. Brain 
homogenates were diluted 6 times into Calibrator Diluent RD5-38, by adding 10 µl of homogenate to 
50 µl of Calibrator Diluent RD5-38. Then, 50 µl of Calibrator Diluent RD5-38 was added to each 
well, followed by pippetting of 50 µl of standards, control, and samples into the same wells, allowing  
any mouse or rat IGF-I present to be bound by the immobilized antibody. After a 2 h incubation at 
room temperature on a horizontal orbital microplate shaker (GFL Shaker 3005
®
) at 500 ± 50 rpm, 
solution was removed from  each well and washed with Wash Buffer to remove any unbound 
compounds. Then, 100 µl of Conjugated containing enzyme-linked polyclonal antibody specific for 
mouse/rat IGF-I was added to the wells and incubated for 2 h. Wells were washed again to remove 
any unbound antibody-enzyme reagent and 100 µl of a substrate solution were added to the wells, 
followed by a 30 min incubation under light protection. After the addition of 100 µl of Stop Solution, 
the enzymatic reaction-induced blue colour turned into yellow. The intensity of the colour measured 
is proportional to the amount of mouse or rat IGF-I bound in the initial step. Optical density of each 
well was measured using a microplate reader (GFL Shaker 3005
®
) at 450 nm, with a correction set to 
540 nm. Sample values were then compared with those from standard curve. Results were expressed 
as mean ±SEM. 
 
2.8. Assessment of brain levels of pyruvate and lactate  
2.8.1. Pyruvate 
In this colorimetric assay (Lactate Assay Kit from Abcam), oxidation of pyruvate by pyruvate 
oxidase generates colour (yellow) and its intensity is proportional to pyruvate levels (Sedewitz et al., 
1984). Following manufacturer‘s instructions, reagents were prepared upon dilution of Pyruvate 
Probe with 220 µl of DMSO (Dimethylsulfoxide) and Pyruvate Enzyme Mix with 220 µl Pyruvate 
Assay Buffer. A Standard Curve was prepared by diluting Pyruvate Standard to a 1 nmol/µl 
concentration (10 µl of the Standard in 990 µl of Pyruvate Assay Buffer). Then, 0, 2, 4, 6, 8, 10 µl of 
this diluted Pyruvate Standard were added into each well and the final volume was adjusted to 50 
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µl/well with Pyruvate Assay Buffer to generate 0, 2, 4, 6, 8, 10 nmol of Pyruvate Standard. Pyruvate 
levels were measured in brain homogenates diluted in 4 volumes of Pyruvate Assay Buffer, and 
centrifuged to get a clear pyruvate extract. Sample volume was adjusted to 50 µl/well with Pyruvate 
Assay Buffer. Then, Reaction Mix containing the following components was prepared: 46 µl 
Pyruvate Assay Buffer; 2 µl Pyruvate Probe; 2 µl Enzyme Mix; and 50 µl of this preparation added 
to each well and incubated for 30 min at room temperature, protected from light. Optical density was 
measured at 570 nm. Results were expressed as mean±SEM. 
 
2.8.2. Lactate 
In the Lactate Assay Kit, lactate is oxidized by lactate dehydrogenase to generate a product 
that interacts with a probe to produce a colour (yellow), which can be detected 
spectrophotometrically at 450 nm. Reagents were prepared according to manufacturer‘s instructions 
by dissolving Lactate Enzyme Mix in 0,22 ml Lactate Assay Buffer, and Lactate Substrate Mix in 
0,22 ml of Lactate Assay Buffer. A Standard Curve was prepared upon reconstitution of the Lactate 
Standard into a 1 mM stock solution (10 µl of the Lactate Standard to 990 µl of Lactate Assay 
Buffer). Then, 0, 1, 2, 3, 4, 5 µl were added to each well. Volumes were adjusted to 25 µl/well with 
Lactate Assay Buffer, to generate 0, 2, 4, 6, 8, 10 nmol of the L(+)-Lactate Standard. Lactate levels 
were determined in brain homogenates diluted with Lactate Assay Buffer, in a proportion of 10 µl of 
sample to 15 µl of buffer, and added to each well. Then, 25 µl of Reaction Mix (containing 23 µl 
Lactate Assay Buffer, 1 µl Lactate Substrate Mix and 1 µl Lactate Enzyme Mix) were prepared and 
added to each well and incubated for 30 min at room temperature, protected from light. Optical 
density was measured at 450nm in a microplate reader (GFL Shaker 3005
®
). Results were expressed 
as mean±SEM. 
 
2.9. Analysis of Adenine Nucleotides and its Metabolites  
 Intracellular adenine nucleotides ATP, ADP, AMP were determined from brain homogenates, 
prepared as previously described. These samples were assayed by separation in a reverse-phase high-
performance liquid chromatography, upon an isocratic elution with 100 mM phosphate buffer 
(KH2PO4), pH 6.5, and 1% methanol, with a flow rate of 1 ml/min, using a Lichrospher 100 RP-18 
(5 µm) column, as described by Stocchi et al. (1985) The chromatographic apparatus used was a 
Beckham-System Gold, consisting of a 126 Binary Pump Model and 166 Variable UV detectors, 
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controlled by a computer. The detection wavelength was 254 nm and the time required for each 
analysis was 6 min. Peak identification was determined by following the retention time of standards.  
Cellular energetic charge was calculated using the formula: ([ATP] + 0.5 [ADP])/([ATP] + 
[ADP] + [AMP]), as described by Pradet and Raymond (1983).  
 
2.10. Data analysis and statistics 
Results are the mean ±SEM of the indicated number of independent experiments, each 
corresponding to a single animal. Parametric tests were used such as Student t test for single 
comparison and one- or two-way ANOVA. A P<0.05 was considered significant. 
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3.1. Analysis of diabetic parameters in YAC128 and WT mice 
Initial experiments were focused on the analysis of total blood glucose levels in both 
heterozygous YAC128 mice and WT littermates, at 6 months of age. Data in Fig. 3.1 show similar 
(although relatively high) glycemia in both animals, under fasting or non-fasting conditions. A 
normal mouse should have blood glucose of around 100 mg/dl (ranging between 60-130 mg/dl) after 
4 h fasting (Wong et al., 1999). Glycemia in WT and transgenic mice was higher than it should be 
expected from normoglycemic mice, namely 212.8 ± 14.71 mg glucose/dl blood for WT and 234.4 ± 
16.72 mg glucose/dl blood for YAC128 mice under feeding conditions (Fig. 3.1A), and 132.8 ± 
11.25 mg glucose/dl blood versus 133.0 ± 13.12 mg glucose/dl blood after 12 h fasting for WT and 
YAC128 mice, respectively (Fig. 3.1B). The observed hyperglycemia may be a symptom of diabetes 
mellitus in these animals. Thus, we further characterized YAC128 mice under a FBV/N strain with 
hyperglycemic background. 
 
 
 
 
 
 
 
 
 
 
The glucose tolerance test measures the clearance of a standardized glucose load from the 
body (Andrikopoulos et al., 2008). No significant changes in blood glucose levels were observed 
during the GTT in YAC128 or WT mice in response to the administration of high glucose levels 
(Fig. 3.2A). The area under the curve (AUC) showed a non-statistical variation of 6.5% between 
both genotypes (Fig. 3.2B). The values for the curves were 37310 ± 3038 mg/dl x h for WT and 
39920 ± 4089 mg/dl x h for YAC128 mice. 
Fig. 3.1. Plasma glucose level in feeding conditions (A) and 12h fasting plasma glucose (B) in WT 
and YAC128 mice. Glucose levels, measured approximately at noon and after 12h fasting, show that 
both WT and YAC128 mice have a hyperglycemic background. The data are the mean±SEM of the 
indicated number of animals. 
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Fig. 3.2. Glucose Tolerance Test (A) and Area Under the Curve (B). Glucose (2 mg/g body weight) was 
intraperitoneally administered. Blood glucose levels were measured after 0, 15, 30, 60 and 120 min. AUC was 
calculated from data in Fig.3.2A. The data are the mean±SEM of the indicated number of animals. 
 
 
 Since no changes were found on the GTT, we also performed the Insulin Tolerance Test 
(ITT) to better characterize the diabetes in these animals and exploit insulin sensitivity/resistance. 
ITT measures the cells ability to use insulin after intraperitoneally administration, by measuring 
blood glucose levels at regular intervals (Carvalho et al., 2005) (Fig. 3.3). YAC128 mice showed 
increased glycemia in response to insulin administration, as compared to WT mice. In YAC mice at 
15 min, blood glucose levels raised significantly compared to WT mice (179.83 ±15.57 mg 
glucose/dl blood for WT versus 256.73 ± 19.21 mg glucose/dl blood for YAC128 mice, p<0.01) and 
then stabilized at 30-90 min. At 60 min, the difference between the two groups was again significant 
(146.92±12.46 mg glucose/dl blood for WT versus 212.09±15.23 mg glucose/dl blood for YAC128 
mice, p<0.05). Interestingly, WT mice did not respond to insulin administration. 
 
 
 In agreement with the alterations found in ITT traces, the AUC for YAC 128 mice was 
23.32 % higher than for WT mice (p<0.05). The mean ± SEM) values calculated for the AUCs were 
14830 ± 1189 mg/dl x h for WT and 19340 ± 1236 mg/dl x h for YAC128 mice. 
A 
B A 
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Fig.3.3. Insulin Tolerance Test (A) and Area Under Curve (B). Insulin (1 µU/g body weight) was 
intraperitoneally administered and serum glucose levels were measured after 0, 15, 30, 60 and 90 min. AUC 
was calculated from data in Fig.3.3A. Data are the mean±SEM of the indicated number of animals. Statistical 
significance: *p<0.05 or **p<0.01 versus WT mice. 
 
 
 
Since insulin resistance appears to occur in controls, and a significant increase in total blood 
glucose levels were found in YAC128 in the ITT test, compared to WT mice, we further determined 
the plasma insulin levels in both groups of mice.  
In YAC128 mice, we observed a tendency for lower plasma levels of insulin; however the values 
were not statistically significant (0.052 ± 0.008 ng/ml/mg protein for WT and 0.0331 ± 0.008 
ng/ml/mg protein for YAC128 mice) (Fig. 3.4 B). 
 
 
Because the neurotrophic factor IGF-1 has a primordial role on glucose metabolism (Petersson et 
al, 2009) and plasma IGF-1 may regulate body weight in HD (Pouladi et al., 2010), we also 
determined plasma levels of IGF-1 in both WT and YAC128 mice under a minimum of 12 h fasting. 
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We observed a slight reduction, although not significant, in plasma IGF-1 levels in YAC128 (19.80 ± 
1.00 ng/ml/mg protein), in comparison with WT (27.89 ± 3.92 ng/ml/mg protein) mice. 
 
 
  
 
  
 
 
 
 
 
 
Fig. 3.4.Plasma Insulin (A) and IGF-1 (B) levels (A) in WT and YAC128 mice. 
Data represent the mean±SEM of the indicated number of animals. 
 
 
 
 
According to Pouladi et al. (2010) plasma IGF-1 levels are correlated with body weight in 
HD mice. Therefore, we measured mice body weight (Fig. 3.5.A) and temperature (Fig. 3.5.B). Both 
WT and YAC128 mice (6 months old), with the same FBV/N background, were overweighed; 
however, we did not find significant differences in body weight between YAC128 and WT mice.  
The normal average rectal temperature for mice is 37.5
o
 C, varying during the day and with 
fasting conditions. Weydt et al. (2006) observed that N171-82Q HD mice develop hypothermia 
associated with impaired activation of brown adipose tissue. In our study, the temperature obtained 
was in the normal range for both groups and no statistical differences were found (36.46 ± 0.46
o
C for 
WT and 36.86 ± 0.33
o
C for YAC128 mice). 
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Fig. 3.5. Characterization of YAC128 and WT mice based on body weight (A) and temperature (B). When 
compared, the two groups are very similar, showing no statistical differences in body weight and body 
temperature. Data represent the mean±SEM of the indicated number of animals. 
 
 
 
3.2. Behaviour analysis 
YAC128 mice model of HD has been described to show motor impairment around 6 months 
of age (Slow et al., 2003). Since the mice used in the present study showed an hyperglycemic 
background, we further analysed if it could influence/aggravate motor performance. Using an 
accelerating rotarod to examine fall latency, YAC128 mice showed a tendency (22.1%) for a 
decrease in latency to fall off the rotarod compared to WT mice, although it did not reach statistical 
significance (Fig. 3.6), suggesting a tendency for motor impairment. 
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Fig. 3.6. Behaviour characterization of YAC128 versus WT mice by the rotarod test. YAC128 and WT mice 
littermates were tested in four trials on an accelerating rotarod at 6 months of age. Data represent the 
mean±SEM of the indicated number of animals. 
 
 
 
Mouse locomotor activity was further measured using an open-field apparatus for a period of 
30 min. YAC128 mice appeared to have similar locomotion and exploration behaviour profiles (Fig. 
3.7). No statistical differences for WT versus YAC128 mice were found for maximal (14.47±0.53 
cm/s versus 14.13 ±0.77 cm/s or mean velocity (1.60±0.21 cm/s versus 1.53±0.19 cm/s) (Fig. 3.7.A). 
The distance travelled (2921 ± 370.0 cm versus. 2750 ± 333.7 cm) (Fig. 3.7.B) and the resting time 
(63.65 ± 3.20 s versus 64.86 ± 3.24 s) were similar between WT and YAC128 mice (Fig. 3.7.C). 
Slow and fast movements did not show any significant differences between groups (Fig. 3.7.D). The 
values obtained for number of slow movements were 261.85 ±32.58 for WT versus 260.47±38.71 for 
YAC128 mice, and for number of fast movements were 392.73±31.25 for WT versus 371.89±22.68 
for YAC128 mice. The latter showed a tendency for a decrease in the number of rearings (Fig. 
3.7.F), which may be due to less anxiety during the test. The permanence time in central square was 
not different between controls and transgenic animals (55.90 ± 3.767% of total time versus 60.48 ± 
3.766% of total time in WT and YAC128 mice, respectively) (Fig. 3.7.E). 
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Fig. 3.7. Behaviour characterization of YAC128 versus WT mice by the openfield test. YAC128 and control 
(WT) littermates were tested in an openfield activity box over a period of 30 min. Six activity parameters were 
measured: A-mean and maximal velocity (cm/s); B-distance travelled (cm); C-resting time (s); D-slow and 
fast movements; E –Time spending in central square; F – Rearing.- Data represent the mean±SEM of the 
indicated number of animals. 
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Given the tendency for a deficit in motor performance in YAC128 mice, as evaluated by the 
rotarod test, which may be caused by neuronal dysfunction (Slow et al., 2003), we further analysed 
central metabolic parameters in order to contextualize those alterations.  
HD is characterized by neuronal impairment, which causes early energy deficit in HD brain 
(Koroshetz et al., 1997). Indeed, our results showed a significant reduction (by approximately 39%) 
in energy charge in YAC128 compared to WT mice (60.97 ± 6.227 % of WT values) (Fig. 3.8.).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.8. Brain energetic charge in YAC128 and WT mice. Brain energetic charge was calculated as ([ATP] + 
0.5 [ADP])/([ATP] + [ADP]+[AMP]). Data expressed as percentages of the ATP/ADP ratio in WT control mice brain 
(considering 0.77 ± 0.09 as 100%). Data are the mean±SEM of the indicated number of animals. Statistical significance: 
* p<0.05, as compared to WT mice. 
 
 
Analysis of brain lactate and pyruvate are useful to screen for impaired energy metabolism. 
Elevated lactate may be suggestive of mitochondrial dysfunction, and is found in several 
neurodegenerative disorders, namely Alzheimer, Parkinson and HD (Bowling and Beal, 1995). Thus, 
lactate/pyruvate (L/P) ratio is a marker of cytoplasmatic redox status and glycolytic function 
(Broderick et al., 2005). These values are typically elevated in disorders of oxidative 
phosphorylation associated with glycolytic overactivation, including HD (Oláh et al., 2008). The 
normal L/P ratio should be <20:1 (Sattler et al., 2008). 
Lactate levels in brain of WT and YAC128 mice did not differ significantly (6.82 ± 1.28 
nm/µl/mg protein for WT and 5.49 ± 0.48 nm/µl/mg protein for YAC128 mice) (Fig. 3.9.A.). 
However, brain pyruvate levels were significantly decreased in YAC128 compared to control mice 
(3.56 ± 0.47 nm/µl/mg for WT versus 1.75 ± 0.39 nm/µl/mg for YAC128 mice, p<0.05) (Fig. 3.9.B). 
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L/P ratio calculated for both groups was in the normal range for mice brain (Sattler et al., 
2008), but YAC128 mice showed a tendency for higher values than the controls (1.91 ± 0.22 for WT 
and 3.86 ± 1.12 for YAC128 mice) (Fig. 3.9.C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IGF-1 and insulin were also measured in total brain homogenates from YAC128 and control 
(WT) mice. Brain insulin and IGF-1 levels were not significantly different between WT and 
YAC128 mice (91.90±14.89 pg IGF-1/ml/mg protein for WT and 74.25±11.00 pg IGF-1/ml/mg 
protein for YAC128 mice; 04175±0.02330 ng insulin /ml/mg protein in WT and 0.03627±0.01378 
ng insulin /ml/mg protein in YAC128 mice). (Fig. 3.10). 
 
Fig. 3.9. Brain levels of lactate (A), pyruvate 
(B) and lactate/pyruvate ratio (C). Lactate and 
pyruvate levels were determined in brain 
homogenates by a Colorimetric assay kit with 
colorimetric detection at 570 nm. Data represent 
the mean±SEM of the indicated number of 
animals. 
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The brain data presented in Fig. 3.10. correspond to a reduced number of animals (n=3 to 5), 
compared to the number of animals used to determine plasma insulin and IGF-1 levels (n= 8 to 12) 
(Fig.3.10). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.10. Brain levels of insulin (A) and IGF-1 (B). Insulin levels were determined in brain homogenates by an 
ELISA kit with colorimetric detection at 450 nm, with a reference wavelength of 620 nm. Data represent the mean±SEM 
of the indicated number of animals. 
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4. Discussion 
YAC128 mice are well characterized in terms of neuronal loss and disease progression but, so 
far, only few studies have focused on peripheral and cerebral metabolism. This mouse strain presents 
several features of HD, namely motor impairment, cognitive deficits and neuronal loss in the 
striatum, an area that comprises a large number (90-95%) of GABAergic medium spiny neurons 
(Slow et al., 2003; van Raamsdonk et al., 2007). 
Interestingly, our study showed that both WT and YAC128 transgenic mice exhibit elevated 
glycemia, compatible with diabetes mellitus, either type 1 or 2, depending on the pathophysiology 
involved, insulin-dependent or -independent, respectively. The current World Health Organization 
diagnostic criteria for diabetes refers that blood glucose levels during fasting should be higher than 
126 mg glucose/dl blood, or 200 mg glucose/dl blood for 2 h blood glucose (WHO, 1996). Indeed, in 
our study both groups had higher values, approximately 133 mg/dl for fasting glucose levels. HD has 
been associated with endocrine abnormalities, namely diabetes, glucose intolerance and insulin 
resistance, even in normoglycemic patients (Podolsky et al., 1997; Ferrer, 1985; Lalić et al., 2008). 
Ferrer (1985) found that 10.5% of HD patients developed diabetes, suggesting that this condition 
may be approximately 7 times more often in these patients than in matched control participants. 
These metabolic changes have been also reproduced in transgenic mice, such as the R6/2, R6/1 and 
N171-82Q mice (Schilling et al., 1999, Bjőrkqvist et al, 2005, Josefsen et al., 2008), suggesting that 
diabetes could be a cardinal feature of HD progression. Bjőrkqvist et al. (2005) have previously 
reported that diabetes in R6/2 mice may be a consequence of pathogenic mechanisms occurring due 
to polyQ inclusions in pancreatic β-cells. 
In our results, using the YAC128 mice, we found that the response to GTT was similar in 
both groups. However, we observed significant changes in the ITT, which could be related with 
insulin sensitivity. Indeed, WT mice did not respond to intraperitoneal injection of 1 µU human 
recombinant insulin/g body weight, whereas HD mice showed some sensitivity to insulin during the 
test, as blood glucose levels tend to decrease. This difference could reflect an insulin resistance in 
WT, since no changes in glucose levels were observed. This was not observed in transgenic mice, 
suggesting that this mechanism may not be responsible for diabetes in these animals. Another 
possible explanation for the poor response in ITT could be related with the dose of insulin used. 
Some studies used higher doses of insulin when performing the ITT in mice (Brüning et al,. 1997).  
Furthermore, others suggested that insulin resistance/insensitivity may not be the major reason for 
developing diabetes, but rather the decrease in insulin expression (Hunt et al., 2005). Interestingly, in 
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the HD mice group we also observed a non significant decrease (by approximately 36%) in the 
amount of circulating insulin, compared to WT mice. Ubiquitinated polyQ inclusions may appear in 
all cells, including pancreatic β-cells, originating aggregates that were suggested to impair insulin 
secretion (Bjőrkqvist et al., 2005). In this regard, a reduction in β-cell mass and in vesicles 
containing insulin were shown as the main causes of hyperglycemia in R6/2 mice expressing the 
exon-1 of human mHtt (corresponding to ~3% of the total protein) (Bjőrkqvist et al., 2005). In HD 
patients some controversial data have been published. Recently, a study concluded that HD patients 
do not have an increased risk of developing diabetes (Boesgaard et al., 2009); however, other studies 
refer a high prevalence of glucose impairment and insulin resistance in HD (for review, Lalić et al., 
2008). 
Hyperglycemia observed in the mice used in our study may also reflect a high caloric diet, 
since normal weight for FBV/N mouse strain is between 25-30 g (Pouladi et al., 2010) and ours 
largely exceeded those values. Previous studies have clearly shown that, when submitted to high-fat 
diet, this strain develops insulin resistance and reduced stimulated insulin secretion (Junghyo et al., 
2009), which may aggravate the hyperglycemia in our predisposing transgenic mice. It was 
previously described that transgenic mice expressing full-length human mHtt, such as BACHD and 
FVB-YAC128 mice, start to gain weight, compared to WT mice, after 2 months of age, which is 
related with the background strain in which they were developed (Van Raamsdonk et al., 2007). The 
YAC128 mice were initially developed in FVB background, but due to several problems associated 
with the strain, a few years later they were backcrossed onto the 129 and C57BL/6 strain 
backgrounds. Both FVB/N and 129 mice are known to be more susceptible to excitotoxicity 
(Schauwecker et al., 1997) than C57BL/6 strain (Leonard et al., 2002). At 12 months of age, striatal 
volume loss was significant in all three strains, being most affected in the FBV strain (van 
Raamsdonk et al., 2007). The severity of the disease phenotype appears to be modulated by the 
background, being the FVB-YAC128 mice the most affected, probably due to the earliest appearance 
of nuclear inclusions of mHtt that correlate with more severe striatal neuropathology (van 
Raamsdonk et al., 2007). Comparing the three backgrounds, FVB, 129 and C57Bl/6 mice, the FVB-
YAC128 mice were the only that presented an increase in body weight and reduced lifespan (van 
Raamsdonk et al, 2007). 
Pouladi et al. (2010) have recently found a positive correlation between plasma levels of IGF-
1, modulated by full-length Htt, and body weight in YAC128 mice. IGF-1 is an essential modulator 
of growth hormone action, acting as a neurotrophic and anabolic factor (for review, Juul, 2003). Our 
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results showed similar IGF-1 levels in WT and YAC128 mice, reflecting their similar body weight. 
In Pouladi‘s study, IGF-1 values were slightly higher in both groups compared to ours. Their plasma 
values varied between 260 and 300 ng IGF-1/ml plasma (being lower for WT mice), and ours were 
226.1±19.6 ng IGF-1/ml plasma for WT and 234.4±32.9 ng IGF-1/ml plasma in YAC128 mice. In 
transgenic mice, plasma levels of IGF-1 and insulin were slightly decreased (although not 
significantly). A possible explanation for this involves the pathophysiology of diabetes, since it has 
been shown that IGF-1 levels decrease with diabetes duration and with increased blood glucose, 
suggesting that IGF-1 may also play a role in peripheral uptake of glucose (Clauson et al., 1998). 
Low circulating levels of IGF-1 after hepatic deregulation in diabetes may underlie not only 
neuropathies associated with diabetes, but also the association of diabetes with different 
neurodegenerative diseases, including HD and Alzheimer disease (Arvanitakis et al., 2004). 
Suppression of IGFBP-1 (IGF-1 binding protein) by insulin may increase bioavailability of IGF-1, 
which could lead to an higher inhibition of growth hormone release in the pituitary gland and a 
consequent reduction in the production of IGF-1 in the liver (Sandhu et al., 2002). In transgenic 
models of hepatic IGF-1 gene deletion, low concentrations of total circulating IGF-1 were associated 
with impaired insulin signalling in skeletal muscle and insulin resistance (Juul, 2003). Moreover, 
diabetes mellitus was previously associated with a decrease in mRNA transcripts for IGF-1, resulting 
in a lower concentration of circulating IGF-1 and in the levels of mRNA for its receptors (Bitar et al., 
1997). In contrast, high total levels of IGF-1 reduced the susceptibility to deterioration of pancreatic 
β-cell mass and function, two important determinants of development of glucose intolerance 
(Clauson, et al., 1998, Sandhu et al., 2002). Recently, a large cohort study showed that adults over 
65 years with glucose intolerance had lower IGFBP-1 levels compared to those with normal glucose 
tolerance (Rajpathak et al., 2008).  
At 6 months of age, our transgenic mice performed slightly worse in the rotarod behaviour 
test than their WT littermates, which is in agreement with the initial description by Slow et al., 
(2003). The phenotype of YAC128, which includes motor impairment, is most likely related to one 
of the hallmarks of HD onset in patients, the striatal atrophy associated with significant neuronal loss 
(Slow et al., 2003). In this model, a linear correlation between rotarod performance at 6 and 9 
months and neuronal loss at 12 months of age was previously established (Slow et al., 2003). 
Moreover, the appearance of early nuclear inclusions of mHtt in striatum seems to precede selective 
degeneration in this brain area, later seen in the disease (van Raamsdonk et al., 2007). 
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In brain, no significant differences in insulin or IGF-1 levels were observed in YAC128 mice 
compared to WT controls, although IGF-1 levels show a tendency to reduction in YAC128 mice. To 
better clarify this trend, a higher number of animals should be further tested. IGF-1 is one of the most 
important activators of Akt signaling pathway, a stimulator of cell growth and proliferation, and a 
potent inhibitor of apoptosis processes (for review, Trejo et al., 2004).  Changes in IGF-1 levels were 
seen in some neurodegenerative disorders, like HD and Parkinson disease and based on its biological 
activities, it is reasonable to assume that IGF-1 depletion may contribute to the progress of 
neurodegenerative processes (for review, Trejo et al., 2004). In HD there is clear evidence that IGF-
1/Akt neuroprotective pathway is altered (Humbert et al., 2002, Colin et al., 2005). A recent study 
found that IGF-1 mRNA expression and protein levels in striatal tissue of YAC18 mice were 
significantly higher than in WT control mice (Pouladi et al., 2010). Since our results were 
determined in total brain, it becomes difficult to confirm the striatal changes.  
The main Gibbs energy source in brain is glucose, which is metabolized in the cytosol, via 
glycolysis, to generate pyruvate, from which the terminal oxidation machinery in the mitochondrial 
compartment produces the major amounts of ATP in neurons (Oláh et al, 2008). It has been widely 
shown that this process is deficient in neurodegenerative diseases and lactate/pyruvate ratio is 
typically elevated, due to increased regional brain lactate production (Martin et al. 2007). Our results 
are in agreement with the results obtained by other studies (Martin et al, 2007; Oláh et al, 2008), 
since YAC128 mice showed a higher lactate/pyruvate compared to WT littermates. Nevertheless, 
mHtt is known to interact with enzymes fundamental to the development of glycolysis, namely 
GAPDH (glyceraldehyde-3-phosphate dehydrogenase), partially inhibiting its function (Junchao et 
al., 2007). It is also widely recognized the relationship between mHtt and mitochondrial dysfunction, 
namely by interfering with oxidative phosphorylation (Bossy-Wetzel et al., 2008). This interaction 
occurs mainly with proteins of the respiratory chain, reducing their activity and compromising 
energy metabolism (Milakovic et al., 2005). MHtt also induces transcriptional dysregulation that 
may contribute to the mitochondrial dysfunction in HD. Studies with PGC-1α (peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha) showed reduced levels in MSN due to 
mHtt-mediated transcriptional blockage, resulting in HD-linked mitochondrial deficits (Cui et al., 
2006; Bossy-Wetzel et al., 2008). PGC-1α is a key transcriptional co-regulator and induces the 
transcription of cellular programs regulating mitochondrial respiration, oxidative stress defense and 
adaptive thermogenesis (Puigserver et al., 2003). Brain lactate content is increased in our transgenic 
model, resembling changes found in HD patients (Martin et al., 2007). Bioenergetic abnormalities 
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were also observed in our study through the reduction in energy charge in YAC128 mice brain. This 
energetic deficit in neurons may worse with neuronal loss and disease progression and may 
aggravate the symptoms of the disease. 
In conclusion, we identified metabolic changes either in WT and YAC128 mice with a FBV 
background. Both have an hyperglycemic background that may influence the results obtained. 
Further studies with a large number of animals will certainly provide a better clarification of the 
influence of an hyperglycemic background in the phenotype and metabolism in this experimental 
model of HD. The data herein presented highly suggest that expression of full-length mHtt in 
YAC128 mice induces both peripheral and central metabolic changes potentially associated with 
decreased plasma insulin levels and deficient brain energy metabolism, which correlate with motor 
impairment. In this perspective, this study may highlight the role of full-length mHtt in the 
susceptibility of HD patients to undergo metabolic deregulation and diabetes. 
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List of Abbreviations 
3-NP, 3-nitropropionic acid 
Aa, amino acids 
ADP, adenosine diphosphate 
Akt, protein kinase B 
AMP, adenosine monophosphate 
AMPA, 3-hydroxy-5-methyl-4-propionate  
Ask1, apoptosis signal-regulating kinase 1 
ATP, adenosine triphosphate  
AUC, area under the curve 
BDNF, brain-derived neurotrophic factor 
CAG, cytosine-adenine-guanine 
cAMP, cyclic-adenosine monophosphate 
CGG, cytosine-adenine-guanine 
CNS, central nervous system 
CREB - cyclic-adenosine monophosphate response element binding protein 
CTG, cytosine- thymine-guanine 
D1, subtype 1 dopamine receptor 
D2, subtype 2 dopamine receptor 
DA, dopamine 
EGF, Epidermal growth factor 
ELISA- Enzyme Linked Immuno Sorbent Assay 
EMG, electromyography 
ER, endoplasmic reticulum 
GAA, guanine–adenine-adenine 
GABA, γ–aminobutyric acid 
GAD, glutamic acid decarboxylase  
GAPDH, glyceraldehyde-3-phosphate dehydrogenase 
GCC, guanine-cytosine-cytosine 
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GLUT, glucose transporter 
GPe, external segment of the globus pallidus 
GPi, internal segment of the globus pallidus 
GTT, Glucose Tolerance Test  
HAP1, Huntingtin associated protein 1 
HD, Huntington‘s disease 
HIP1, huntingtin-interacting protein 1 
HIP2, huntingtin-interacting protein 2 
HIPPI, HIP1-protein interactor  
HSPs, Heat shock proteins 
Htt, huntingtin  
Htt
NT
, N-terminal fragments 
IGF-1, insulin growth factor 1  
InsP3R1, inositol 1,4,5-trisphosphate receptors 
IP31, inositol (1,4,5)-trisphosphate type 1 
IT15, Interesting Transcript 15 gene 
ITT, Insulin Tolerance Test 
KA, Kainic acid 
L/P ratio, lactate/pyruvate ratio 
MA, malonic acid  
mGluR, metabotropic glutamate receptors 
mHtt, mutant huntingtin  
mPTP, mitochondrial permeability transition pore 
MSN, medium spiny neurons 
NAD
+
, nicotinamide-adenine dinucleotide 
NMDAR, N-methyl-D-aspartate receptor 
NR2, NMDA receptor subunit 
NTL, nucleus tuberalis lateralis 
PBS, phosphate buffered saline 
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PCR, polymerase chain reaction 
PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
polyQ, polyglutamine(s) 
QA, Quinolinic acid 
REST, repressor element-1 transcription factor 
ROS, reactive oxygen species 
SBMA, Spinal and Bulbar Muscular Atrophy  
SDH, succinate dehydrogenase 
SNARE, ethylmaleimide-sensitive fusion protein attachment protein receptor  
SNpc, substantia nigra pars compacta 
SNr, substantia nigra pars reticulata 
SP1, specific protein-1 
STN, subthalamic nucleus 
TAFII, TATA-associated factors 
TBP, TATA-binding protein 
UPS, ubiquitin–proteasome system 
UPS, ubiquitin–proteasome system 
VA/VL complex, ventral anterior and ventral lateral thalamic nuclei  
WHO, World Health Organization 
YAC, yeast artificial chromosome 
YAC, yeast artificial chromosome 
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